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ABSTRACT 
Epigenetic mechanisms are essential for normal cell development. Alteration in those 
normal processes leads to malignant cell transformation and with this to cancer development.  
Use of inhibitors that alter the epigenetics of DNA methylation and histone post translational 
modifications has lead to the exploration of the epigenetic mechanism involved in silencing of 
tumor suppressor genes in cancer, including acute myeloid leukemia (AML). Moreover, 
combinations of inhibitors that target various epigenetic enzymes have being recognized to be 
more effective in the re-activation of tumor suppressor genes than individual drug treatments. 
Here, we reported that p15, p21 and E-cadherin genes are more effectively re-expressed using a 
combination of DNA methyltransferase and histone methyltransferase inhibitors in AML cell 
lines. Re-expression of hypermethylated p15 and E-cadherin genes required reduced levels of 
promoter histone 3 lysine 9 (H3K9) methylation rather than inhibition of DNA methylation 
itself. Moreover, induction of p21 expression was associated with changes in promoter histone 
3 lysine 9 methylation (H3K9Me) by achieving inhibition of the histone methyltransferase, 
SUV39H1, activity. Altogether, our results highlight the potential of combining epigenetic 
drugs in the re-activation of epigenetically silenced tumor suppressor genes and the need for 
evaluating histone methyltransferases as therapeutic targets for treatment of acute myeloid 
malignancies.   
ii 
 
ACKNOWLEDGEMENTS  
 
I want to give many thanks to my supervisor Dr. Ron Geyer, without his patience, guidance and 
directions the achievement of this project could not be finished. Acknowledgements, to Dr. 
Roesler for giving me continued encouragement and guidance. To my entire committee member 
Dr. Khandelwal, Dr. Wilson and Dr. Roesler for the guidance and continue feedback in this 
research project. To Margaret Ross for her infinite help and patience in assisting me with 
everything related to the graduate program. 
  
I would like to especially thank Asha and Erika for their continued help and guidance in many 
of my experiments. Also, I want to thank all the members of Dr. Geyer Lab, Wendy Bernhard, 
Khris Barreto, Landon, Wayne Hill and specially to Alberto Aparicio, Theodora Zlateva and 
Bharathi Vellalore for their friendship and support during my graduate studies.  
I also wish to thank Jennifer Nyarko for being a friend and support during this time as well as 
Family Gomez and all my friends in Saskatoon.  
Special  thanks  to my Family and my  fiancé and friend Juan for their encouragement, support 
and love throughout these years.  
Finally, I want to dedicate this achievement to the memory of my mother and Elaine, two great 
women whose encouragement taught me that for more difficult that a situation would be you 
always need to keep your head high and have the strength to continue in life. 
 
Thank you all. 
 
iii 
 
  
TABLE OF CONTENTS 
 
ABSTRACT ................................................................................................................................... i 
ACKNOWLEDGEMENTS .......................................................................................................... ii 
LIST OF TABLES ...................................................................................................................... vii 
LIST OF FIGURES ................................................................................................................... viii 
LIST OF ABBREVIATIONS ...................................................................................................... xi 
1. INTRODUCTION ..................................................................................................................... 1 
2. REVIEW OF THE LITERATURE ........................................................................................... 2 
2.1. Molecular basis of cancer ................................................................................................... 2 
2.1.1. Multistep molecular carcinogenesis ............................................................................. 2 
2.2. Chromatin organization and regulation .............................................................................. 3 
2.2.1. Chromatin structure ...................................................................................................... 3 
2.3. Epigenetics .......................................................................................................................... 4 
2.3.1. DNA methylation ......................................................................................................... 4 
2.3.1.1. CpG island hypermethylation ................................................................................ 6 
2.3.1.2. DNA methyltransferases ........................................................................................ 6 
2.3.1.3. DNA methyltransferases inhibitors ........................................................................ 7 
2.3.1.4. 5-Aza-2-deoxycytidine (DAC) .............................................................................. 9 
2.3.2. Histone methylation ................................................................................................... 11 
2.3.2.1. Histone 3 lysine 9 methylation (H3K9Me) .......................................................... 13 
2.3.2.2. Histone methyltransferase SUV39H1 .................................................................. 13 
2.3.2.3. Histone methyltransferase G9a ............................................................................ 14 
2.3.3. Histone methyltransferase inhibitors .......................................................................... 15 
2.3.3.1. Chaetocin.............................................................................................................. 15 
2.3.3.2. BIX-01294 ........................................................................................................... 16 
2.3.4. Regulation of epigenetic events in cancer .................................................................. 17 
2.4. Acute myeloid leukemia ................................................................................................... 19 
2.5. Tumor suppressor genes in acute myeloid leukemia ........................................................ 21 
iv 
 
2.5.1. p15 
(INKb)
 gene ............................................................................................................. 21 
2.5.2. p21 
(WAF1/CIP1) 
gene ...................................................................................................... 23 
2.5.3. E-cadherin gene .......................................................................................................... 24 
3. EXPERIMENTAL OBJECTIVES .......................................................................................... 26 
4. MATERIALS AND METHODS ............................................................................................ 27 
4.1. Reagents and suppliers ..................................................................................................... 27 
4.2. Oligonucleotides ............................................................................................................... 28 
4.3. Antibodies ......................................................................................................................... 30 
4.4. Cell lines and culture conditions ....................................................................................... 30 
4.5. Drug treatments ................................................................................................................ 31 
4.6. Molecular techniques  ....................................................................................................... 31 
4.6.1. DNA extraction from AML cells ............................................................................... 31 
4.6.2. RNA extraction from AML cells ................................................................................ 31 
4.6.3. Reverse transcriptase polymerase chain reaction (RT-PCR) ..................................... 32 
4.6.4. Agarose gel electrophoresis ........................................................................................ 32 
4.6.5. Real time PCR ............................................................................................................ 32 
4.7. DNA methylation analysis ................................................................................................ 33 
4.7.1. Sodium bisulfate modification ................................................................................... 33 
4.7.2. Methylation specific PCR .......................................................................................... 34 
4.7.3. Pyrosequencing .......................................................................................................... 34 
4.8. Cell cycle .......................................................................................................................... 35 
4.9. MTT spectrophotometric assay ........................................................................................ 35 
4.10. Chromatin immunoprecipitation assay ........................................................................... 37 
4.11. Statistical analysis ........................................................................................................... 37 
5. RESULTS ................................................................................................................................ 38 
5.1. p15, p21 and E-cadherin genes are silenced in AML cell lines ........................................ 38 
5.1.1. Analsis of p15, p21 and E-cadherin expression and promoter methylation in AML 
cell lines ........................................................................................................................ 38 
5.2. The effect of DAC, BIX-01294 and chaetocin on AML cell proliferation ...................... 46 
5.3. Effect of DAC on p15, p21 and E-cadherin gene expression ........................................... 50 
5.3.1. DAC-induced expression of p15, p21 and E-cadherin genes ..................................... 50 
v 
 
5.3.2. DAC-induced p15 and E-cadherin expression by reducing promoter methylation ... 50 
5.3.3. DAC-mediated induction of p15, p21 and E-cadherin correlated with changes in 
H3K9 methylation ........................................................................................................ 62 
5.4. Effect of BIX on p15, p21 and E-cadherin gene expression ............................................ 65 
5.4.1. BIX treatment did not re-activate expression of p15 and E-cadherin genes in 
AML cell lines .............................................................................................................. 65 
5.4.2. BIX reduced H3K9 methylation levels at p15, p21 and E-cadherin .......................... 65 
5.4.3. BIX did not induce changes in promoter methylation at p15 and E-cadherin 
promoters ...................................................................................................................... 66 
5.5. Effect of chaetocin on p15, p21 and E-cadherin expression ............................................ 73 
5.5.1. Chaetocin-induced re-expression of p15, p21 and E-cadherin ................................... 73 
5.5.2. Chaetocin-mediated expression of p15, p21and E-cadherin caused changes in 
H3K9 methylation ........................................................................................................ 73 
5.5.3. Chaetocin enhanced p15 and E-cadherin expression without promoter 
demethylation ............................................................................................................... 74 
5.6. Combinatorial treatments of DAC, BIX and chaetocin on AML cell proliferation ......... 81 
5.7. Combinatorial treatments of DAC, BIX and chaetocin influenced gene activation in 
AML cells ............................................................................................................................ 93 
5.7.1. Chaetocin and DAC in combination reactivated expression of p15 and E-cadherin 
genes by reducing levels of promoter methylation and H3K9 tri-methylation ............ 93 
5.7.2. Chaetocin and DAC in combination reactivated expression of p21 gene by 
causing changes on H3K9 di-methylation ................................................................... 99 
5.7.3. Co-treatment of BIX and DAC caused differential expression of p15, p21 and E-
cadherin genes in AML cell lines ............................................................................... 101 
5.7.4. Combination of histone methyltransferase inhibitors: BIX and chaetocin induced 
differential p15 and E-cadherin expression and increased H3K9 trimethylation ...... 108 
5.7.5. BIX and chaetocin in combination induced expression of p21 gene, which was 
associated with increased promoter H3K9 di- and tri-methylation ............................ 108 
6. DISCUSSION ........................................................................................................................ 112 
6.1. Epigenetic regulation of p15, p21, and E-cadherin genes upon treatment with DAC, 
BIX and chaetocin ........................................................................................................... 114 
vi 
 
6.2. Epigenetic regulation of p15, p21, and E-cadherin genes upon treatment with 
combinations of epigenetic inhibitors ............................................................................. 116 
7. FUTURE DIRECTIONS ....................................................................................................... 120 
8. REFERENCES ...................................................................................................................... 121 
vii 
 
LIST OF TABLES 
 
Table 2.1. Lysine methyltransferases and their link to cancer .................................................... 12 
Table 4.1. List of reagents and suppliers used in this study ....................................................... 27 
Table 4.2. Comercially available kits used in this study ............................................................ 28 
Table 4.3. Sequences and optimal annealing temperatures of primers used in this study  ......... 29 
Table 4.4. Antibodies used in chromatin immunoprecipitation assays ...................................... 30 
Table 5.1. Chromatin immunoprecipitation assays of the effect of epigenetic drugs on H3K9 
methylation in AML-193 cell line ................................................................................ 63 
Table 5.2. Median doses in AML cell lines by treatment of chaetocin and BIX  ...................... 83 
Table 5.3. CI values for combination of BIX with chaetocin in AML cell lines ....................... 89 
Table 6.1. Epigenetic regulation of p15 gene upon treatment with epigenetic inhibitors, 
DAC, BIX and chaetocin ........................................................................................... 112 
Table 6.2.  Epigenetic regulation of E-cadherin gene upon treatment with epigenetic 
inhibitors, DAC, BIX and chaetocin .......................................................................... 113 
Table 6.3. Epigenetic regulation of p21 gene upon treatment with epigenetic inhibitors, 
DAC, BIX and chaetocin ........................................................................................... 113 
viii 
 
LIST OF FIGURES 
Figure 2.1.  Chemical basis of DNA methylation. ....................................................................... 5 
Figure 2.2.  Chemical structures of DNMT inhibitors ................................................................. 8 
Figure 2.3.  Representation nucleoside analogues incorporation into the DNA in proliferating 
cells ............................................................................................................................... 10 
Figure 2.4.  Chemical structure of chaetocin .............................................................................. 16 
Figure 2.5.  Chemical structure of BIX-01294. .......................................................................... 17 
Figure 2.6.  Myeloid cell differentiation ..................................................................................... 20 
Figure 2.7.  Schematic representation of check points control during G1-S progression .......... 22 
Figure 4.1.  Schematic representation of the chemical conversion of cytosine to uracyl........... 33 
Figure 4.2.  Pyrosequencing analysis of CpG methylation ........................................................ 36 
Figure 5.1.  p15, p21, and E-cadherin expression and promoter methylation in AML cell 
lines .............................................................................................................................. 39 
Figure 5.2.  p15, p21 and E-cadherin MSP and ChIP PCR product location ............................. 40 
Figure 5.3.  p15, E-cadherin, and p21 promoter methylation in AML cell lines ....................... 41 
Figure 5.4.  DNA pyrosequencing analysis of p15 promoter methylation in AML cell lines ... 42 
Figure 5.5. DNA pyrosequencing analysis of E-cadherin promoter methylation in AML cell 
lines .............................................................................................................................. 43 
Figure 5.6. DNA pyrosequencing analysis of p21 promoter methylation in AML cell lines .... 45 
Figure 5.7. Proliferation of AML cell lines treated with BIX and chaetocin ............................. 47 
Figure 5.8. Effect of BIX-01294 on the cell cycle in AML cell lines ........................................ 48 
Figure 5.9. Effect of chaetocin on the cell cycle in AML cell lines ........................................... 49 
Figure 5.10. Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell 
lines .............................................................................................................................. 51 
Figure 5.11. Effect of DAC on p15 promoter methylation in AML-193 cell line ..................... 52 
Figure 5.12. Effect of DAC on p15 promoter methylation in Kasumi cell line ......................... 53 
Figure 5.13. Effect of DAC on E-cadherin promoter methylation in AML-193 cell line .......... 54 
Figure 5.14. Effect of DAC on E-cadherin promoter methylation in Kasumi cell line .............. 55 
Figure 5.15. Effect of DAC on p21 promoter methylation in AML-193 cell line ..................... 58 
Figure 5.16. Effect of DAC on p21 promoter methylation in Kasumi cell line ......................... 61 
ix 
 
Figure 5.17. Chromatin immunoprecipitation analysis of the effect of DAC on H3K9 di- and 
tri-methylation and H3 associated with p15, E-cadherin, and p21 promoters in AML 
cell lines   ...................................................................................................................... 64 
Figure 5.18.  Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell 
lines .............................................................................................................................. 67 
Figure 5.19.  Chromatin immunoprecipitation analysis of the effect of BIX on H3K9 di- and 
tri-methylation and H3 associated with the p15, E-cadherin, and p21 promoter in 
AML cell lines .............................................................................................................. 68 
Figure 5.20.  Effect of BIX on p15 promoter methylation in AML-193 cell line ...................... 69 
Figure 5.21.  Effect of BIX on p15 promoter methylation in Kasumi cell line .......................... 70 
Figure 5.22.  Effect of BIX on E-cadherin promoter methylation in AML-193 cell line .......... 71 
Figure 5.23.  Effect of BIX on E-cadherin promoter methylation in Kasumi cell line .............. 72 
Figure 5.24.  Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell 
lines .............................................................................................................................. 75 
Figure 5.25.  Chromatin immunoprecipitation analysis of the effect of chaetocin on H3K9 
di- and tri-methylation and H3 associated with the p15, E-cadherin, and p21 
promoter in AML cell lines .......................................................................................... 76 
Figure 5.26.  Effect of chaetocin on p15 promoter methylation in AML-193 cell line.............. 77 
Figure 5.27.  Effect of chaetocin on p15 promoter methylation in Kasumi cell line ................. 78 
Figure 5.28.  Effect of chaetocin on E-cadherin promoter methylation in AML-193cell line ... 79 
Figure 5.29.  Effect of chaetocin on E-cadherin promoter methylation in Kasumi cell line ...... 80 
Figure 5.30.  Dose median effect (Dm) plots of BIX and chaetocin in AML-193 cell line ....... 84 
Figure 5.31.  Dose median effect (Dm) plots of BIX and chaetocin in KG-1a cell line ............ 85 
Figure 5.32.  Dose median effect (Dm) plots of BIX and chaetocin in Kasumi cell line ........... 86 
Figure 5.33.  Drug combination effect of BIX and chaetocin in AML-193 cell line ................. 90 
Figure 5.34.  Drug combination effect of BIX and Chaetocin in KG-1a cell line ..................... 91 
Figure 5.35.  Drug combination effect of BIX and Chaetocin in Kasumi cell line .................... 92 
Figure 5.36.  Real time PCR analysis of p15, p21, and E-cadherin expression upon 
treatment with chaetocin and DAC in combination in AML cell lines ........................ 94 
Figure 5.37. Effects of chaetocin and DAC combinatorial treatment on p15 promoter 
methylation in AML-193 cell line ................................................................................ 95 
x 
 
Figure 5.38. Effects of chaetocin and DAC combinatorial treatment on p15 promoter           
methylation in Kasumi cell line ................................................................................... 96 
Figure 5.39. Effects of chaetocin and DAC combinatorial treatment on E-cadherin promo-
ter methylation in AML-193 cell line .......................................................................... 97 
Figure 5.40.  Effect of chaetocin and DAC combinatorial treatment on E-cadherin promoter 
methylation in Kasumi cell line ................................................................................... 98 
Figure 5.41.  Chromatin immunoprecipitation analysis of the effect of DAC and chaetocin 
in combination on H3K9 di- and tri-methylation and H3 associated with the p15,  
E-cadherin and p21 promoter in AML cell lines ........................................................ 100 
Figure 5.42.  Real time PCR analysis of p15, p21 and E-cadherin expression upon treatment 
with BIX and DAC in combination in AML cell lines .............................................. 102 
Figure 5.43.   Effect of BIX and DAC combinatorial treatment on p15 promoter methylation 
in AML-193 cell line. ................................................................................................. 103 
Figure 5.44.   Effect of BIX and DAC combinatorial treatment on p15 promoter methylation 
in Kasumi cell line. ..................................................................................................... 104 
Figure 5.45. Effect of BIX and DAC combinatorial treatment on E-cadherin promoter 
methylation in AML-193 cell line  . ........................................................................... 105 
Figure 5.46. Effect of BIX and DAC combinatotial treatment on E-cadherin promoter 
methylation in Kasumi cell line. ................................................................................ 106 
Figure 5.47. Chromatin immunoprecipitation analysis of the effect of DAC and BIX in 
combination on H3K9 di- and tri-methylation and H3 associated with the p15, E-
cadherin, and p21 promoter in AML cell lines .......................................................... 107 
Figure 5.48.  Real time PCR analysis of p15, p21, and E-cadherin expression upon 
treatment with chaetocin and BIX in combination in AML cell lines ....................... 110 
Figure 5.49. Chromatin immunoprecipitation analysis of the effect of chaetocin and BIX in 
combination on H3K9 di- and tri-methylation and H3 associated with the p15, E-
cadherin and p21 promoter in AML cell lines ........................................................... 111 
  
xi 
 
LIST OF ABBREVIATIONS 
 
ABL 
AML 
AML1 
ANK 
BAALC 
BCR 
Albenson kinase gene 
Acute myeloid leukemia 
Acute myeloid leukemia gene 1 
Ankyrin 
Brain and acute leukemia, cytoplasmic gene 
Breakpoint cluster region gene 
BIX 
CBF 
BIX-01294 
Core binding factor 
CDK 
CDKI 
Cyclin dependent kinase 
Cyclin dependent kinase inhibitor 
CDH 
cDNA 
CEBPA 
Cadherin 
Complementary DNA 
CCAAT/ enhancer binding protein alpha 
ChIP 
CML 
Chromatin immunoprecipitation  
Chronic myeloid leukemia 
DAC 
DCK 
5-Aza- -deoxycytidine 
Deoxycytidine kinases 
DMSO Dimethyl sulfoxide 
DNMT DNA methyltransferase 
ES 
ETO 
Embryonic stem cells 
Eight-twenty-one gene 
FAB 
FLT-3 
French-American-British classification 
FMS-like tyrosine kinase 3 
GAPDH 
GM-CSF 
Glyceraldehyde-3-phosphate dehydrogenase 
Granulocyte macrophage colony stimulating factor 
H2A Histone 2A 
H2B Histone 2B 
H3 Histone 3 
H4 Histone 4 
xii 
 
H3K9 Histone 3 lysine 9 
H3K9Me Histone 3 lysine 9 methylation 
H3K9Me2 Histone 3 lysine 9 di-methylation 
H3K9Me3 Histone 3 lysine 9 tri-methylation 
HDAC Histone deacetylase 
HMT 
HP1 
Histone methyltransferase 
Heterochromatin protein 1 
HPRT Hypoxanthine-guanine phosphoribosyltransferase 
IL-3  
ITD 
Interleukin 3 
Internal tandem duplications 
MDS 
MDR 
Myeloid dysplastic syndrome 
Multidrug resistance gene 
MSP Methylation specific PCR 
MTT 
Myc 
MYH11 
MOZ 
NPM1 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Myelocytomatosis factor 
Myosin heavy chain 11 
Monocytic leukemia zinc finger protein 
Nucleophosmin mutation 
PCR 
PCNA 
PML 
Polymerase chain reaction 
Proliferating cell nuclear antigen 
Promyelocytic leukemia gene 
PMSF 
RARA 
RAS 
Phenylmethylsulfonyl fluoride 
Retionic acid receptor alpha 
Small GTPases proteins 
Rb Retinoblastoma 
RT-PCR 
SAM 
SET 
TGF-  
Reverse transcriptase polymerase chain reaction 
S-adenosylmethionin 
Suv3-9 Suppressor of Variegation, Enhancer of Zeste, Trithorax 
Transforming growth factor beta 
TSA Trichostatin A 
 
1 
 
1. INTRODUCTION 
 
Cancer has been classically recognized as a genetic disease. However, since the discovery 
of epigenetics, the cancer paradigm has changed and now it is recognized as a genetic and 
epigenetic disease.  
Epigenetics involve the study of heritable changes on gene expression without any 
alteration in the DNA sequence. Thus, epigenetic mechanisms are essential for the maintenance 
of gene expression patterns in a cell and for normal cellular development. The major hallmark 
of epigenetics is that epigenetic changes are reversible, which suggests therapies could be 
developed to reverse and restore epigenetic aberrations that occur in cancer (Sharma et al., 
2010).  
Major breakthroughs in the discovery of epigenetic drugs have contributed to our 
understanding of epigenetic silencing of tumor suppressor genes in cancer (Cameron et al., 
1999; Bachman et al., 2003; Ekmekci et al., 2004; Baylin, 2005). For example, combinations of 
epigenetic drugs, such as DNA methyltransferase (DNMT) and Histone deacetylase (HDAC) 
inhibitors have been found to be more effective in reactivating silenced tumor suppressor genes 
and in reducing tumor formation compared to individual drug treatments (Cameron et al., 1999; 
Zhu and Otterson, 2003). Hence, studies involving combinations of epigenetic-enzyme 
inhibitors might help to elucidate the epigenetic components involved in aberrant gene silencing 
and might contribute to the use of more effective treatments in cancer therapy. 
The objective of this thesis was to investigate mechanisms involved in the epigenetic 
silencing of tumor suppressor genes in acute myeloid leukemia (AML) and to evaluate 
epigenetic drug combinations that allow re-expression of tumor suppressor genes. The 
following literature review will provide the current knowledge related to the molecular basis of 
cancer, AML, chromatin structure, general concepts of epigenetics, and a brief description of 
DNMT and HMT inhibitors and their potential use in epigenetic therapy. Emphasis will be 
placed on the regulation of epigenetic events in cancer and some important tumor suppressor 
genes in AML.  
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2. REVIEW OF THE LITERATURE 
 
2.1. Molecular basis of cancer 
 
2.1.1. Multistep molecular carcinogenesis 
Classically, cancer has been recognized as a heterogeneous disease that is caused by 
progressive genetic abnormalities driven by mutational events that evoke a normal cell to 
become a cancer cell through a process called carcinogenesis (Hanahan et al., 2000). More 
recently, it has been recognized that cancer is also driven by epigenetic changes that do not 
affect the DNA sequence but cause alterations on gene activity by mechanisms that involve 
DNA methylation and histone modifications (Jones et al., 2007; Sharma et al., 2010). 
Carcinogenesis does not occur from a single event; rather it is due to the accumulation of 
sequential molecular changes that lead to the inactivation of tumor suppressor genes and the 
activation of oncogenes, which alter cell phenotypes and bring about tumor formation. Tumor 
cells are diverse and heterogenous but they all share common features of deregulated cell 
proliferation and apoptosis (Evan et al., 2001).  
In 1990, Fearon proposed a genetic, multi-step model for colorectal cancer, suggesting that 
as a cell moves through the various stages of malignancy, hyperplasia, metaplasia, neoplasia, 
pathways (Fearon and Vogelstein, -
model in which a dominantly inherited predisposition to cancer entails a germline mutation, 
while tumorigenesis requires a second, somatic mutation. In contrast, non-hereditary cancer of 
the same type requires the same two hits but both are somatic (Knudson, 1996).   
In leukemia, attempts to elucidate genetic and molecular steps that drive a variety of 
leukemic transformations have been investigated over the past three decades (Chen et al., 
2010). For example, chronic myeloid leukemia (CML) is recognized to be caused in 95% of 
cases by the chromosomal translocation t (9; 22), which produces the fusion between the 
breakpoint cluster region gene and the Albenson kinase gene (BCR-ABL). Acute myeloid 
leukemia (AML) is recognized as heterogeneous disease that is caused by a variety of recurring 
chromosomal aberrations and genetic mutations (Melo et al., 2007; McCormack et al., 2008). 
However, these malignancies evolve into other types of leukemic forms and causes of these 
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transformations are still poorly understood. Due to the heterogeneity and complexity of 
leukemias, a multistep carcinogenesis model has not yet been established. Identifying 
molecular, genetic, and epigenetic irregularities involved in each type of cancer is essential for 
understanding the biological mechanisms, for predicting cancer development, and for 
identifying appropriate therapeutic approaches. 
 
2.2. Chromatin organization and regulation 
 
2.2.1. Chromatin structure 
Chromatin structure defines the state in which genetic information is organized within a 
cell. The fundamental unit of chromatin is the nucleosome, which is composed of 147 base 
pairs of DNA wrapped around an octamer of core histone proteins, consisting of two copies of 
each histone protein: H2A, H2B, H3 and H4. Each of these core histones contains two major 
domains; a structured globular domain that mediates DNA-histone and histone-histone 
interactions and an amino domain or tail that is outside the core and serves as a substrate for 
histone modifying enzymes, which introduce post-translational modification such as 
acetylation, methylation, phosphorylation, ubiquitylation, and sumoylation (Kouzarides, 2007). 
Chromatin is compacted into a higher order structure forming a 30 nm condensed fiber by 
repetitive folding of adjacent nucleosomes. Chromatin condensation is dynamic and structurally 
heterogenous and it is present principally in two different forms, heterochromatin and 
euchromatin. Heterochromatin is compact and associated with transcriptionally inert DNA 
regions. Heterochromatin is principally found at the chromosome centromere and telomeric 
regions (Martin et al., 2005). Euchromatin is characterized by uncondensed chromatin, which is 
accessible for gene activation (Cosgrove and Wolberger, 2005; Bernstein, 2007). Dynamic 
changes in chromatin structure greatly influence abilities of genes to be activated or silenced. 
These changes are principally driven by enzymatic modifications, such as DNA methylation 
and histone protein modification and they are broadly defined as epigenetic changes (Bernstein, 
2007).  
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2.3. Epigenetics 
The term epigenetics was first defined by Waddington in the 1940s, as 
 (Waddington, 
1942). Regardless of its many definitions, epigenetics is currently defined as the study of 
heritable changes in gene expression that occur without any changes in the genomic DNA 
sequence (Jones and Baylin, 2002). Epigenetic modifications are transmitted from one 
generation of cells to the next and heritable gene expression patterns are mediated by particular 
combinations of DNA methylation and posttranslational histone modifications (Sharma et al., 
2010). These modifications regulate genome functioning and alter the structural dynamic of the 
chromatin, causing inactivation or activation of specific genes. Alteration in these processes 
results in dysregulation of gene expression profiles, causing permanent silencing of tumor 
suppressor genes and activation of oncogenes that lead to cancer development.  However, 
events that lead to initiation and progression of these changes are still not completely 
understood (Feinberg, 2007; Jones et al., 2007; Sharma et al., 2010).  
 
2.3.1. DNA methylation 
DNA methylation is the only type of chemical modification that takes place on the DNA 
molecule without altering the DNA sequence itself (Espada and Esteller, 2010). In mammals, 
DNA methylation occurs through the addition of a methyl group at the C-5
 
position of cytosine 
in CpG dinucleotides, which is catalyzed by DNA methyltransferases (DNMTs) (Figure 2.1). 
CpG islands correspond to a genomic sequence that has high content of CG dinucleotides and 
typically occurs near the transcription start site of genes (Gardiner-Garden and Frommer, 1986). 
Approximately 60% of human gene-promoters are associated with CpG-rich regions. Even 
though only a relatively small fraction of these sequences become methylated, changes in 
methylation are necessary during cell development and differentiation as well as to maintain the 
stability of the cell (Bernstein, 2007). However, hypermethylation of CpG islands can stably 
repress genes and cause misregulation that are involved in cancer development (Mund et al., 
2006; Jones et al., 2007).   
DNA methylation mainly mediates gene silencing by either blocking transcription factors 
from accessing DNA binding sites or providing sites for methyl-binding proteins, which can 
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mediate gene repression through interactions with histone related enzymes, such as histone 
deacetylases (HDACs) and histone methyltransferases (HMTs) (Sharma et al., 2010).  
 
 
 
Figure 2.1. Chemical basis of DNA methylation. DNA methylation in mammalian genome 
occurs almost exclusively in cytosine residues contained in CpG dinucleotides and it essentially 
takes place to preserve genome DNA methylation (a) and to alter gene expression patterns 
through de novo methylation (b). (a) The pattern of symmetrically methylated CpG 
dinucleotides is copied and maintained during DNA replication in a process catalyzed by DNA 
methyltransferases. (b) DNA methyltransferases use S-adenosyl-L-methionine (SAMe) as the 
source of methyl groups, producing S-adenosyl-homocysteine (SAH). DNA methyltransferases 
catalyze the addition of met -position of the pyrimidine ring of cytosine. 
(This figure was adapted and modified from Espada and Esteller, 2010). 
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2.3.1.1. CpG island hypermethylation 
A cancer epigenome is marked by a global DNA hypomethylation and site-specific CpG 
island promoter hypermethylation (Esteller, 2007). Site specific DNA hypermethylation was 
initially associated with tumorogenesis when loss of function of the tumor suppressor gene Rb 
was discovered to be caused by promoter CpG hypermethylation (Greger et al., 1989). 
Following this discovery, various other tumor suppressor genes, including p16 (Gonzalez-
Zuleta et al., 1995), p15 (Herman et al., 1997) MLH1 (Kane et al., 1997), and E-cadherin 
(Graff, 1995; Corn et al., 2000; Melki et al., 2000) were shown to undergo tumor-specific 
repression by promoter hypermethylation in a variety of cancers. 
DNA hypermethylation also indirectly silences other genes by repressing transcription 
associated-factors and DNA repair genes, which interferes with the normal cellular processes 
(Sharma et al., 2010). Although, silencing of tumor suppressor genes by DNA 
hypermethylation is well established in cancer, it is not clear how genes are targeted to be 
silenced by this modification. Currently, DNA methylation markers are being investigated as 
prognostic factors, diagnostic tools, and treatment response predictors in a variety of cancers 
including leukemia, and demethylating agents are being used in cancer therapy (Esteller, 2007). 
 
2.3.1.2. DNA methyltransferases  
In mammals, DNA methylation is a process modulated by three DNA methyltransferase 
(DNMT) enzymes, DNMT1, DNMT2, and DNMT3, which includes DNMT3a and DNMT3b 
members. These DNMTs catalyze two important methylation patterns: methylation 
maintenance and de novo methylation (Zhu and Otterson, 2003).  
DNMT1 is the largest methyltransferase with a molecular mass of 184 kDa (Smith et al., 
1992) and it is the principal isoform responsible for methylation maintenance. In proliferating 
cells, DNMT1 has a high affinity for hemi-methylated DNA and it is found to be associated 
with the replication stage of the cell cycle; ensuring preservation of the pre-existing methylation 
pattern in the new synthesized cell during DNA replication (Leonhardt et al., 1992; Li et al., 
1993). In human cells, a reduction in catalytic activity of DNMT1 results in a massive 5-methyl 
cytosine (5mC) demethylation, nuclear disorganization, genomic instability, and loss of cell 
viability (Espada and Esteller, 2010). Abnormalities in DNMT1 are found in a variety of cancer 
(Rhee et al., 2000; Lee et al., 2001; Peng et al.,2005, but loss in DNMT1 activity, in contrast to 
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normal cells, is required for activation of hypermethylated tumor suppressor genes that suppress 
tumor progression in malignant cells (Chen et al., 2007). DNMT1 has also been reported to 
interact with histone methyltransferase enzymes such as G9a and SUV39H1 to stably silence 
genes (Cedar and Bergman, 2009; Sharma et al., 2010).  
DNMT2 is much smaller than DNMT1 with a predicted molecular weight of 45 kDa.  
Although DNMT2 contains the conserved methyltransferase motif, which is characteristic of   
DNMTs, this enzyme has very low DNA methyltransferase activity in comparison with 
DNMT1 and DNMT3. In addition, it has been reported that depletion of the DNMT2 gene in 
mice does not show phenotype changes and thus the function of DNMT2 still remains unknown 
(Okano et al., 1998; Herman et al., 2003). 
DNMT3a and DMT3b isoforms have a molecular size between 100-130 kDa and they carry 
out de novo DNA methylation using unmethylated DNA as a substrate. However, several 
reports have shown that DNMT1 as well as DNMT3a and DNMT3b have both de novo and 
maintenance methylation in vivo, cooperating to establish global DNA methylation patterns in 
the cell (Kim et al., 2002). These enzymes are mainly expressed in embryonic and non-
differentiated cells and they are critical for embryonic development (Okano et al., 1999). 
DNMT3L is also a member of the DNMT3 family but unlike DNMT3a/3b it lacks DNA 
methyltransferase activity (Ooi et al., 2007). The function of this enzyme is to recruit DNMTs 
to DNA by binding to histone H3 in the nucleosomes. DNMT3a and DNMT3b are associated 
with SET domain proteins such as histone methyltransferases G9a, SUV39H1, and SUV39H2, 
which are required for heterochromatinization and histone lysine methylation (Cedar and 
Bergman 2009).  
  
2.3.1.3. DNA methyltransferase inhibitors 
Since the discovery of the association between promoter hypermethylation of tumor 
suppressor genes and the development of cancer, DNA demethylating agents (in reference to 
DNMT inhibitors, which lead to the loss of methyl groups from DNA) have emerged as 
therapeutic reagents for reversing this process. The most extensively studied DNMT inhibitors 
are 5-aza-cyditine and 5-aza- -deoxycytidine (DAC) (Figure 2.2). These chemotherapeutic 
agents are nucleoside analogues that incorporate into the DNA to inhibit the activity of DNMT 
enzymes (Zhu and Otterson, 2003; Hellebrekers et al., 2007). However, a major disadvantage 
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of these aza-nucleosides is their instability in aqueous solution. This limitation has prompted 
the development of more stable nucleosides analogues, such as 5-fluoro-
zebularine, enabling oral administration of the drugs. Even though zebularine is more stable and 
less toxic, it requires higher concentrations to cause an effect in comparison with DAC (Cheng 
et al., 2004). Non-nucleoside analogue DNMT inhibitors have also been discovered as well as 
natural products derived from teas (Hellebrekers et al., 2007).  Most DNMT inhibitors are not 
specific for a particular DNMT enzyme, which may result in unfavourable effects and 
toxicities. Consequently, new compounds specific for DNMT types are being developed, such 
as MG98, which is an oligonucleotide antisense inhibitor of DNMT1 (Hellebrekers et al., 
2007).  
 
 
 
 
 
 
 
 
Figure 2.2. Chemical structures of DNMT inhibitors. 5-aza- -deoxycytidine (DAC) and 5-aza-
cytidine. The difference between these compounds is that the ribose at position 3 of the cytosine 
ring in 5-aza-cytidine is replaced with deoxyribose in DAC. 
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2.3.1.4. 5-Aza- -deoxycytidine (DAC) 
The remarkable discovery that treatment of cells with the cytotoxic agents, 5-azacytidine 
and DAC, inhibits DNA methylation, induces expression of genes, and causes differentiation of 
cancer cells, led to the use of these drugs in cancer therapy. DAC is a derivate of 5-azacytidine 
and a more potent demethylating agent (Jain et al., 2009). This compound is also a cytidine 
analogue that is incorporated into the DNA in place of the natural base cytosine during DNA 
replication. Once incorporated into the DNA, this compound irreversibly binds to DNMT1, 
leading to a rapid loss of DNMT1 activity and therefore to the demethylation of DNA (Figure 
2.3) (Chen et al., 2004; Hellebrekers et al., 2007). Accumulated evidence from studies on 
hypermethylated silenced genes has demonstrated that DAC induced the re-expression of tumor 
suppressor genes in cancer cells if methylation is the primary reason for gene silencing (Jones 
and Baylin et al., 2002; Daskalakis et al., 2002, Chen et al, 2004). In addition, DAC can also 
induce expression of apoptotic genes and DNA damage response genes, such p53 (Chen et al., 
2004).   
The Food and Drug Administration has recently approved the use of 5-azacytidine and 
DAC for treatment of myelodysplastic syndromes (MDS) and promising results have emerged 
from the treatment of hematological malignancies, such as AML and CML (Plickmark et al., 
2007; Jain et al., 2009). Although, DAC provides an effective treatment of these cancers, 
toxicity on normal cells have been a concern due to the incorporation of this compound into 
DNA. However, since this drug only acts in dividing cells and tumor cells are rapidly dividing 
in comparison with normal cells, it is thought that treatment with this drug may have a minimal 
effect on normal cell populations, making this compound a good candidate in cancer therapy 
(Sharma et al., 2010). 
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Figure 2.3. Nucleoside analogue (NA) incorporation into the DNA of proliferating cells. 
Nucleoside analogues enter the cell via specific nucleoside transporters. Once inside the cell, 
nucleoside analogues are phosphorylated by deoxycytidine kinases (DCK) to produce active -
triphosphate derivatives. Nucleoside analogues are incorporated into newly synthesized DNA, 
where they covalently interact with DNMTs, inhibiting DNA methylation. (Adapted from 
Galmarini et al., 2001; Ewald et al., 2008).  
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2.3.2. Histone methylation 
Post-translational modifications that occur on histone tails have been recognized to play 
important roles in regulation of chromatin structure (Esteller 2007; Hublitz et al., 2009). 
Histone methylation is catalyzed by histone methyltransferases (HMTs) and it usually occurs on 
the Arginine (R) and Lysine (K) residues. Histone methylation, in contrast to other 
modifications, does not alter the charge of the histone tail but influences the basicity and 
hydrophobicity of histones and their affinity to other proteins, such as transcription factors for 
chromatin regulation (Esteller, 2007; Hublitz et al., 2009). 
The Histone methyltransferase enzymes can be subdivided into three classes; SET domain 
(Suv3-9 Suppressor of Variegation, Enhancer of Zeste, Trithorax) lysine methyltransferases, 
non-SET domain lysine methyltransferases, and arginine methyltransferases (Kouzarides, 2007; 
Albert et al., 2010; Spannhoff et al., 2009).  
Lysine methyltransferases are highly specific. They usually modify one specific lysine 
residue on a single histone, which can be linked either to activation or repression of 
transcription. Lysine methylation is predominantly found within tails of histone 3 and histone 4 
(H3 and H4); however the core globular domain of histones can also undergo methylation, for 
example at lysine 79 of H3 (Martin et al., 2005; Kouzarides, 2007; Albert et al., 2010). Lysine 
residues can be mono-, di-, or tri-methylated and more than twenty lysine methyltransferase 
enzymes have been identified in humans. However, misregulation of many of these 
methyltransferases has been linked to cancer (Table 2.1) (Martin et al., 2005; Albert et al., 
2010). 
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Table 2.1. Lysine methyltransferases and their link to cancer. Enzymes that fall into the same 
family are grouped. 
 
Enzyme Lysine residues Links to cancer 
SUV39H1/2 H3K9 Increased mRNA levels in colon cancer patients 
(Kang et al., 2007) 
B-cell lymphoma in knockout mice (Peters et al., 
2001) 
G9a H3K9 Contributes to H3K9 dimethylation involved in 
tumor suppressor gene silencing (McGarvey et al., 
2006) 
EU-HMTase1 H3K9 Overexpressed in gland tumors (Aniello et al., 
2006) 
SETDB1/ESET H3K9 Association with DNMTs  in promoter silencing in 
tumors (Li et al., 2006) 
MLL1 H3K4 Mutations/rearrangements involved in 
leukemogenesis (Chen et al., 2010) 
MLL3 H3K4 Intragenic mutations in colorectal cancer (Sjoblom 
et al., 2006) 
SMYD2 H3K4 Overexpressed in hepatocellular carcinoma 
(Skawran et al., 2008) 
Suppression of p53 transcriptional activity (Huang 
et al., 2007) 
SMYD3 H3K4 Overexpressed in colorectal and hepatocellular 
carcinoma (Hamamoto et al., 2004) 
Overexpression enhanced breast cancer cell growth 
(Hamamoto et al., 2006) 
DOT1L H3K79 Involved in leukemogenesis (Chen et al., 2010) 
SET8/PR-SET7 H4K20 Suppresses p53 dependent transcription (Shi et al., 
2007) 
SUV20H1/2 H4K20 Decrease of H4K20 tri-methylation is associated to 
lymphoma cancer and Knock-downed SUV20H1/2 
mice (Fraga et al., 2005) 
EZH2 H3K27 
  
Associated with aggressive tumor growth in several 
tumor types, including lymphomas and melanomas 
(Bachmann et al., 2006) 
Marker for precancerous state and aggressive breast 
cancer (Ding et al., 2006;  (Collet et al., 2006) 
Promotes proliferation and invasiveness of prostate 
cancer cells (Bryan et al., 2007)  
Biomarker for poor prostate cancer prognosis 
(Cooper et al., 2007)  
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2.3.2.1. Histone 3 lysine 9 methylation (H3K9Me) 
Lysine methylation is an abundant epigenetic modification found in all eukaryotes and it is 
associated with different states of chromatin (Kouzarides, 2007). In histone 3 (H3), mono- (Me) 
and di-methylation (Me2) of lysine 9 (K9) is associated with activation of transcription, 
whereas tri-methylation (Me3) is commonly involved in transcriptional silencing. Despite 
H3K9 di-methylation being related with transcriptional activation, it can also be associated with 
gene repression in euchromatin and heterochromatin regions, which suggest that H3K9 
methylation might have different functions depending on whether it occurs in coding regions or 
in gene-promoters (Rice et al., 2003; Martin and Zhang, 2005; Kouzarides, 2007). In mammals, 
several lysine methyltransferases target different levels of H3K9 methylation, such as 
SUV39H1/2, G9a, GLP, and RIZ (Martin et al., 2005; Hublitz et al., 2009). 
McManus and colleagues reported a dynamic role for H3K9 methylation in controlling the 
cell cycle. They revealed that mono- and di-methylation levels of H3K9 remain unaltered 
during cell cycle progression, while H3K9 tri-methylation levels increased for maintenance of 
chromosomal segregation in the transition from late G2 into mitosis. They also observed that 
H3K9 tri-methylation mark is rapidly lost after completion of mitosis and it returns to basal 
levels by early G1. Importantly, this study demonstrated that absence of pericentromeric H3K9 
tri-methylation correlates with an increase in abnormal mitosis, premature chromatid 
separation, genomic instability, and cancer predisposition (McManus et al., 2006). Thus, 
perturbations of H3K9 methylation patterns and enzymes associated with these modifications 
leads to misregulation of the cell cycle control and then to the aberrant silencing of tumor 
suppressor genes that control proliferation in various forms of cancer (Sharma et al., 2010).  
 
2.3.2.2. Histone methyltransferase SUV39H1 
SUV39H1 was the first histone methylation enzyme discovered in humans and it is 
responsible for tri-methylation of lysine 9 at histone 3 (H3K9). This enzyme belongs to the SET 
domain lysine methyltransferases class. The SET domain of SUV39H1 carries out the H3K9 
methyltransferase activity using monomethylated H3K9 as a substrate to finally induce tri-
methylation at the same residue (Aagaard et al., 1999; Rea et al., 2000; Peters et al., 2003). 
The role of SUV39H1 and its associated H3K9 methyltransferase activity in 
heterochromatin function was first indicated by the association with the heterochromatin protein 
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HP1 (Aagaard et al., 1999; Rea et al., 2000). Subsequent studies showed that SUV39H1-
mediated H3K9 methylation provides a binding site for chromodomain transcriptional repressor 
HP1 proteins, which in turn recruit other transcriptional repression machinery, such as DNA 
methyltransferases and histone deacetylases (HDACs) to achieve gene silencing (Wang et al., 
2000). Moreover, evidence supports that SUV39H1 and SUV39H2 recruit DNMT3a and 
DNMT3b in order to methylate CpG sites in the satellite sequence (Cedar and Bergman, 2009). 
For example, a loss of H3K9 methylation in SUV39H1 knockout embryonic stem (ES) cells 
decreases DNMT3b-dependent CpG methylation at major centromere satellites. This data 
suggests that DNA methylation may be a secondary event in gene silencing (Lehnertz et al., 
2003). In addition, alteration of SUV39H1 expression has been related to cancer development 
and silencing of tumor suppressor genes, such as p16, p15, and E-cadherin (Bachman et al, 
2003; Albert et al., 2010; Lakshmikuttyamma et al., 2010) 
 
2.3.2.3. Histone methyltransferase G9a 
G9a belongs to the SET domain lysine methyltransferase class and in contrast to 
SUV39H1; G9a regulates H3K9 mono- and di-methylation in euchromatin regions and has a 
major function in transcriptional control. The dominant role of this enzyme in euchromatin 
regions is supported by the observation that the H3K9 methylation pattern is severely 
eliminated in G9a-deficient mice and cells (Tachibana et al., 2002, 2005).  
G9a, apart from having the SET catalytic domain, also contains an ankyrin (ANK) domain, 
which has been recently recognized to be associated with DNMT3a and DNMT3b and is 
involved in directing de novo DNA methylation (Cedar and Bergman, 2009). Accordingly, 
Epztejn-Litman and Dong reported that H3K9 methylation is eliminated upon inactivation of 
G9a SET domain without affecting DNA methylation; instead it was recognized that the 
ankyrin domain physically interacts with DNMT3a and DNMT3b to establish DNA 
methylation (Epztejn-Litman et al., 2008; Dong et al., 2008). This data indicates that de novo 
DNA methylation is not dependent on G9a-mediated histone modification per se; however, G9a 
is required for recruiting DNMT3a and DNMT3b for stable gene silencing (Epztejn-Litman et 
al., 2008; Dong et al., 2008). Conversely, it was reported that G9a directly interacts with 
DNMT1 to establish a coordinated mechanism for DNA and histone methylation during cell 
replication and that this interaction perhaps depends on G9a methyltransferase activity (Esteve 
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et al., 2006). Increased levels of G9a have been linked to gain in promoter H3K9 dimethylation 
in tumor suppressor genes, consequently leading to their silencing in various types of cancer 
(McGarvay et al., 2006; Kondo et al., 2008).  
 
2.3.3. Histone methyltransferase inhibitors  
Since the discovery that epigenetic aberrations can be reverted in cancer cells, a number of 
DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors have been 
introduced, extensively studied, and clinically tested for use in cancer therapy (Hellebrekers et 
al., 2007). More recently, histone methyltransferase (HMTs) inhibitors have been found to 
enhance anti-cancer therapy due to their ability to block repressive histone lysine methylation 
marks, such as H3K9 di- and tri-methylation. To date, two lysine methyltransferase inhibitors 
have been identified: chaetocin and BIX-01294. 
 
2.3.3.1. Chaetocin 
Chaetocin, a fungal mycotoxin isolated from the fermentation broth of Chaetomium 
minutum, belongs to a class of molecules called 3-6-epidithiodiketopiperazines (Figure 2.4). 
Functionally, chaetocin was found to inhibit the Drosophila melanogaster histone 
methyltransferase SU(VAR)3-9 and its human ortholog, the H3K9 trimethylase SUV39H1 
(Greiner et al., 2005). Although chaetocin is effective in inhibiting SUV39H1 activity, its role 
in reactivation of silenced genes by promoter H3K9 demethylation is limited. Attempts to 
elucidate this role have been investigated. Recently, it was reported that treatment of cancer 
cells with chaetocin results in activation of tumor suppressor genes and a drastic decrease in 
promoter H3K9 di- and tri-methylation (Cherrier et al., 2009; Lakshmikuttyamma et al., 2010). 
Interestingly, chaetocin reactivates genes that have been silenced by promoter 
hypermethylathion in leukemia cells, which suggests that inhibition of SUV39H1 activity 
perhaps is required to abolish DNMTs interaction and therefore the recruitment of other 
repressive marks crucial for aberrant gene silencing (Lakshmikuttyamma et al., 2010). In 
addition to its demethylating function, chaetocin seems to be a selective drug for myeloma 
therapy, affecting myeloma cancer cells without toxicity on normal bone marrow and B-cells 
(Isham et al., 2007), which makes this compound a promising target for treatment of myeloid 
malignancies, including leukemia. 
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Figure 2.4. Chemical structure of chaetocin. 
 
 
2.3.3.2. BIX-01294  
BIX-01294 (BIX) is a diazepi-quinazolin-amine derivative that selectively impairs the 
histone methyltransferase activity of G9a and the generation of H3K9 di-methylation (Figure 
2.5). BIX does not compete with the cofactor S-adenosylmethionine (SAM) and does not inhibit 
SUV39H1 activity (Kubicek et al., 2007; Chang et al., 2009). 
It has been reported that G9a induces inactivation of post-implantation genes by the 
accumulation of H3K9 di-methylation marks during embryogenesis. In mouse ES cells and 
embryonic fibroblast cells, treatment with BIX results in a significant reduction of di-methyl 
H3K9 in proximal-promoters, thereby allowing the transient reversal of this mark and the 
activation of G9a target genes (Kubicek et al., 2007). BIX has not been tested for its ability to 
reactivate tumor suppressor genes in cancer. The evaluation of BIX treatment in cancer cells 
might be of crucial importance for activation of tumor suppressor genes that contain H3K9 di-
methylation as a repressive mark and more importantly BIX could be used to potential reverse 
misregulated G9a activity that leads a faulty cell development in cancer stem cells (Wen et al., 
2009). 
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Figure 2.5. Chemical structure of BIX-01294. 
 
 
2.3.4. Regulation of epigenetic events in cancer 
Knowing the order in which epigenetic changes occur might have important implications 
for understanding normal cell development and tumorigenesis. Previously it was recognized 
that DNA hypermethylathion was the major epigenetic deregulation linked to cancer. Cancer 
cells are subject to abnormal DNA methylation within promoters of tumor suppressor genes and 
this event is responsible for inhibiting their function and inducing cell proliferation (Jones and 
Baylin, 2002). However, these observations have been restricted to re-activation of silenced 
genes by promoter demethylation using the demethylating agent 5-aza-2´-deoxycytidine (DAC) 
(Jones and Baylin, 2002; Herman and Baylin, 2003). Conversely, it was shown that DAC also 
induces expression of non-hypermethylated genes. Tumor suppressor genes that have been 
reactivated by DAC still maintain heterochromatic marks, such as histone H3K9 and H3K27 
methylation, in their promoters. Thus, DAC treatment does not return reactive genes to a fully 
euchromatin state (Zhu and Otterson, 2003; McGarvey et al., 2006). In this regards, 
transcriptional silencing of cancer-associated genes depends not only upon DNA methylation, 
but it is also associated with multiple promoter chromatin modifications, including histone 
deacetylation, histone methylation of H3 at lysine 9, and loss of the transcriptional activating 
mark H3K4 di- and tri-methylation (Coombes et al., 2003; Scott et al., 2006; Sharma et al., 
2010). Despite the fact that the exact sequence of events is not known, the current study of 
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epigenetic inhibitors has opened the possibility to investigate dynamic alterations and 
interactions of epigenetic modified marks that are linked to silenced-promoter of tumor 
suppressor genes. 
Several reports have shown that aberrant gene silencing is associated with a concomitant 
loss of histone acetylation. Trichostatin A (TSA) and other HDAC inhibitors have been 
associated with the reactivation of silenced genes; however there is evidence suggesting that 
they cannot reactivate the expression of hypermethylated tumor suppressor genes (Herman et 
al., 1997; Cameron et al., 1999; Suzuki et al., 2002; Hellebrekers et al., 2007). Combinatorial 
therapy with histone deacetylase and DNA methyltransferase  inhibitors enhances re-expression 
of several genes silenced by promoter hypermethylation to levels higher than when they are 
induced with DNMT inhibitors alone (Zhu and Otterson, 2003; Hellebrekers et al., 2007). 
Nonetheless, HDAC inhibitors are unable to block the re-silencing of genes after treatment with 
DNMT inhibitors. This data then indicates that DNA methylation is a dominant event over 
histone deacetylation (Egger et al., 2007). In this view, histone methylation seems to play an 
important role in hypermethylated gene silencing. For example, alterations in H3K9 and H3K27 
methylation patterns are associated with aberrant gene silencing in various forms of cancer and 
more importantly DNA regions that have been hypermethylated are often pre-marked with tri-
methyl H3K27 mark in cancer ES cells (Ohm et al., 2007; Schlesinger, et al., 2007). H3K9 
methylation can be rapidly reversed by treatment with DAC, suggesting a direct relationship 
between DNA and histone methylation in gene inactivation (Nguyen et al., 2002; Coombes et 
al., 2003).  
Currently, histone methyltransferase inhibitors have being targeted in epigenetic therapy for 
re-activation of tumor suppressor in cancer, due to its ability to interact between each other and 
form repressor silencing complexes that inactivate gene expression (Fritsch, et al., 2010).  So 
far, it has been reported that treatment with chaetocin, the specific inhibitor of H3K9 
trimethylase SUV39H1, induces the expression of hypermethylated p15 and E-cadherin genes 
without any changes in promoter methylation (Lakshmikuttyamma et al., 2010).  Moreover, 
treatment with chaetocin induces re-expression of the non-hypermethylated gene p21 by 
reducing levels of trimethyl H3K9 and by blocking the interaction between SUV39H1 and the 
repressor CTIP2 protein (Cherrier et al., 2009). This suggests that histone methylation itself 
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may be a dominant event that leads to transcriptional gene silencing or it cooperatively interact 
with DNMTs to initiate aberrant promoter methylation.  
Altogether, these findings reinforce the potential of histone methyltransferase inhibitors in 
re-expressing tumor suppressor genes. As well it highlights the need for further development of 
combinatorial treatments that reverse aberrant gene silencing in cancer. 
 
2.4. Acute myeloid leukemia 
 Acute myeloid leukemia (AML) is a heterogeneous clonal disorder of hematopoietic 
progenitor cells, which is characterized by the rapid proliferation of abnormal cells that are 
accumulated in the bone marrow and interfere with the production of normal blood cells (Figure 
2.6). AML is the most common type of leukemia in adults with an equal frequency in males and 
females, and like other cancers, its incidence increases with age (Estey and Dohner 2006; 
Deschler et al., 2006).  
Although the etiology of leukemia is unknown, recurrent genetic and chromosomal 
alterations are associated with leukemia etiology, and they are recognized to be crucial to the 
disease pathogenesis (Chen et al., 2010). The genotypic diversity of AML depends on 
numerous chromosomal translocations that result in the generation of oncogenic fusion 
proteins, such as AML1-ETO (generated by a translocation between 8 and 21, t (8; 21)), PML-
RARA, t (15; 17), CBF-MYH11, t (16; 16), and MOZ-CBP, t (8; 16), etc), as well as point 
mutations involved in specific genes (MDR, FLT-3 ITD, C/EBP , BAALC, NPM). These 
genetic alterations confer proliferative and survival advantage to hematopoietic progenitors 
with a minimal capacity to differentiate (Frankfurt et al., 2007; Chen et al., 2010). Besides 
those genetic factors, aberrant epigenetic regulation of genes in AML is being recognized as 
becoming increasingly important to the pathogenesis of AML (Plass et al., 2008). Promoter 
hypermethylation of several tumor suppressor genes with well-established functions in cell 
cycle control, apoptosis, or DNA repair are associated with the development of the disease 
(Agrawal et al., 2007; Melki et al., 1999; Melki et al., 2000; Ekmekci et al., 2004; Shimamoto 
et al., 2005).  
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Figure 2.6. Myeloid cell differentiation. Illustrated are the differentiation pathways of blood 
cell development. The bone marrow makes progenitor stem cells that develop into mature blood 
cells over time. Progenitor stem cells may become a myeloid stem cell or lymphoid stem cells. 
The myeloid stem cell differentiates into one of the five types of mature blood cells: erythroid, 
platelets, macrophage, neutrophil, eosinophil, and basophil. Acute myeloid leukemia (AML) is 
originated when a disorder of the hematopoetic progenitor stem cell occurs, causing the 
accumulation of abnormal cells that cannot be differentiated into the variety of normal blood 
cells (mature blood cells). 
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2.5. Tumor suppressor genes in acute myeloid leukemia  
Tumor suppressor genes encode proteins that are involved in receiving or processing of 
growth inhibitory signals and therefore they are very important in preventing malignant 
transformation. Like almost all genes, tumor suppressor genes are present in two copies per cell. 
ypothesis explains the loss-function of these genes in cancer 
development, meaning that both alleles of a gene have to be inactivated in order to promote 
unregulated cell proliferation (Knudson, 1996; Krug et al., 2002).  However, it was proposed 
that the function of some tumor suppressor genes can be disrupted solely by alteration of one 
allele, resulting in a dominant negative mode of action that compromise the normal function of 
its counterpart in the same cell (Blagosklonny, 2000). Genetic disruption and epigenetic 
inactivation of several tumor suppressor genes has been associated with AML development 
(Krug et al., 2002; Chen et al., 2010). Particularly, genes that are involved in cell cycle control, 
such as cyclin dependent kinases (CDK) inhibitors p15 and p21 have been recognized to be 
silenced by aberrant epigenetic modifications in AML (Herman, 1997; Scott et al, 2006; 
Lakshmikuttyamma et al., 2010). In addition, the E-cadherin gene, a potential suppressor of 
metastasis, is also epigenetically silenced in AML (Corn et al., 2000; Melki et al., 2000).  
 
2.5.1. p15 
(INK4b)
 gene  
p15 belongs to the INK4 family that consist of a group of small (15-19 KDa) ankyrin repeat 
proteins. p15
INK4b
, p16
INK4a
, p18
INK4c
, and p19
INK4d
 function as inhibitors of CDK4 and CDK6 
(Sharpless, 2005). P16
INK4a
 (p16) and p15
INK4b
 (p15) proteins bind directly to CDK4 and CDK6 
blocking their association with regulatory D cyclins and enabling other cyclin-dependent kinase 
inhibitors, such as p21CIP1 and p27KIP1 to associate with and inhibit the assembly of cyclin 
E/A-CDK2 complexes. The lack of cyclin E/A-CDK2 complexes in turn inhibits 
phosphorylation of retinoblastoma (Rb) family members causing inactivation of proteins 
involved in DNA synthesis and thus arresting the cell cycle progression in G1-phase (Figure 
2.7) (Massagué,  2004; Sharpless, 2005; Gil and Peters, 2006). p15, p16, and ARF share the 
same locus INK4a/ARF/INK4b, but they play independent roles in tumor suppression (Gil and 
Peters, 2006). INK4b gene expression can be activated by the regulation of proteins such as the 
transforming growth factor beta ( ) and small GTPases (RAS) and it can be repressed by 
myelocytomatosis (MYC) factor, which usually leads to the unregulation of other several genes 
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involved in cell proliferation (Hannon and Bench, 1994; Warner et al., 1999; Seosane et al., 
2001).  
 
 
 
 
 
 
Figure 2.7. Schematic representation of check points control during G1-S progression. By 
binding directly to CDK4 and CDK6, INK4a/b proteins block the assembly of catalytically 
active cyclin D-CDK complexes and enable the cyclin-dependent kinase inhibitors p21CIP1 
and p27KIP1 to associate with and inhibit cyclin E/A-CDK2. This in turn inhibits 
phosphorylation of retinoblastoma (Rb) family members, blocking the release and activation of 
E2F-dependent genes and the activation of proteins involved in DNA synthesis. The net result 
is the promotion of cell cycle arrest in G1-phase during G1-S progression (Adapted from 
Malumbres and Barbacid, 2009). 
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The INK4 genes are commonly silenced by mutations and epigenetic modifications in 
diverse types of cancers (Okamoto et al., 1994; Gil and Peters, 2006; Kim and Sharpless, 2006; 
Malumbres and Barbacid, 2009). Point mutations and intragenic alterations in the locus target 
INK4a rather than ARF or INK4b (Sharpless, 2005). However, most alterations occur by 
epigenetic inactivation of p16 and p15 genes due to hypermethylation of their promoters or by 
deletions in the 9p21 chromosome region (Krug et al., 2002). p15 is frequently silenced by 
promoter hypermethylation in myeloid dysplastic syndrome (MDS) and AMLs (Herman et al., 
1997; Chim et al., 2001; Christiansen et al., 2003). Hypermethylation of p15 occurs in the 
majority of patients with AML and it has been strongly associated with disease progression 
(Woong et al., 2000; Krug et al., 2002). Therapeutic DNA demethylating agents, such as DAC 
have been used for the re-activation of hypermethylated genes in AML cell lines (Jain et al., 
2009). Interestingly, it was recently showed that p15 is not only re-expressed by promoter 
demethylation, but blocking histone H3K9 methylation with histone methyltransferases 
inhibitors also induced p15 expression in AML cell lines (Lakshmikuttyamma et al., 2010). 
This suggest that use of combinatorial therapies might efficiently leads to the re-expression of 
silenced tumor suppressor genes rather than the use of epigenetic inhibitors alone.  
 
2.5.2. p21 
(WAF1/CIP1)
 gene  
p21 gene encodes a small 165 amino acid protein that belongs to the CIP and KIP family of 
CDK inhibitors that includes p21CIP/WaFI (p21), p27KIP1 (p27), and p57KIP2 (p57) (Sherr 
and Roberts, 1995). The p21 protein contains two functional domains, an amino-terminal CDK 
interaction region that is sufficient for CDK inhibition, and a carboxy-terminal region that binds 
proliferating cell nuclear antigen (PCNA), a processivity factor associated with DNA 
polymerase- r proteins involved in DNA synthesis (Chen et al., 1995).  
p21 inhibits cell cycle progression primarily by blocking CDK2 activity, which is required 
not only for the phosphorylation of Rb family proteins, which releases and activates E2F-
dependent gene expression, but also for the activation of proteins directly involved in DNA 
synthesis (Massagué, 2004; Malumbres and Barbacid, 2005). Thus, suppression of p21 activity 
is essential for checkpoint control in G1/S progression within the cell cycle (Figure 2.7) 
(Malumbres and Barbacid, 2005). Moreover, by inhibiting cell cycle progression, p21 also 
allows DNA repair processes to occur by binding to proliferating cell nuclear antigen (PCNA), 
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which interferes with PCNA-dependent DNA polymerase activity, inhibiting DNA replication 
(Chen et al., 1995; Luo et al., 1995; Moldovan et al, 2007). The ability of p21 to promote cell 
cycle arrest and DNA repair responses can be dependent or independent of the tumor 
suppressor protein p53 activity. However, other evidence indicates that p21 mediates its various 
biological activities independent of the classical p53 tumor suppressor pathways (Abbas and 
Dutta 2009).  
p21 expression can be regulated by a variety of transcriptions factors, such as p53, Sp1, or 
C/EBP for a positive regulation and MYC and inactivation of p53 for a negative regulatory 
effect (Gartel and Tyner, 1999; Abbas and Dutta, 2009). p21 deregulation has been reported in 
various forms of cancer (Shiohara et al., 1994; Poole et al., 2004). Accordingly, several studies 
have shown that p21 deficiency increased frequency and development of spontaneous tumors in 
mice (Martin-caballero et al., 2001). Moreover, evidence suggests that p21 is crucial for 
maintaining stem cell potential by restricting their self-renewal capacity in various tissues 
(Cheng et al., 2000; Kippin et al., 2005).  
Epigenetic silencing of p21 has been reported in human cancer and DNA methylation and 
histone deacetylation are crucial for this silencing (Suzuki et al., 2002; Lagger et al., 2003; 
Scott et al., 2006). p21 is unmethylated in most types of cancers; however some lung cancer 
cell lines show hypermethylation within the CpG islands of the p21 gene-promoter (Zhu and 
Otterson, 2003; Ying et al., 2004; Scott et al., 2006). Treatment with demethylating agents 
induces re-expression of p21 by mechanisms that are dependent or independent of promoter 
demethylation and by HDAC inhibition (Zhu et al., 2004; Scott et al., 2006). Scott and 
colleagues reported that p21 gene is epigenetically silenced in AML by a mechanism that does 
not involve promoter hypermethylation, due to the lack of p21 promoter methylation in AML 
cell lines. Moreover, they also showed that treatment with DAC and TSA cause p21 re-
expression by release of HDAC1 (Scott et al., 2006). In AML cell lines, similar studies have 
not been performed to determine the effect of histone methylation on p21 gene re-expression. 
 
2.5.3. E-cadherin gene 
E-cadherin gene encodes a glycoprotein that is involved in calcium dependent cell-cell 
adhesion. E-cadherin is one of the most important molecules in cell adhesion in epithelial 
tissues and is also considered a potential invasion/metastasis suppressor. Loss of E-cadherin 
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function contributes to the progression of several types of cancers such as gastric, breast, 
colorectal, thyroid, and ovarian cancer and recently it has been recognized as potential 
invasion/metastasis suppressor in leukemia (Hirohashi, 1998; Melki et al., 2000). The 
inactivation of the E-cadherin gene occurs in undifferentiated solid tumors by both genetic and 
epigenetic mechanisms (Yoshiura et al., 1995). In addition, it has been shown that E-cadherin 
gene expression is reduced or absent in leukemia due to the promoter hypermethylation (Melki 
et al., 2000). Dysfunction of this gene in AML is important to pathogenesis and therefore it 
could have clinical importance in the treatment of AML (Shimamoto et al., 2005). Recently, it 
was reported that E-cadherin silencing can be reverted either by promoter demethylation or by 
inhibition of promoter H3K9 tri-methylation in AML cell lines (Lakshmikuttyamma et al., 
2010).  
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3. EXPERIMENTAL OBJECTIVES 
 
The efficient reactivation of epigenetically silenced genes requires the development of 
combinatorial epigenetic therapies that reverse aberrant chromatin modifications and lead to 
transcriptional activation of tumor suppressor genes in cancer.  The objective of this study was 
to investigate epigenetic mechanisms involved in the re-expression of three tumor suppressor 
genes: p15, p21 and E-cadherin in AML using the DNMTinhibitor, 5-Aza- -deoxycytidine 
(DAC), and the HMT inhibitors, BIX-01294 (BIX), and chaetocin.  
 
To achieve this goal, the following aims were undertaken:  
 
1. Evaluate the p15, p21, and E-cadherin promoter methylation status using methylation 
specific PCR and DNA pyrosequencing.  
 
2. Determine the effect of DAC, BIX, and chaetocin on acute myeloid leukemia cell 
proliferation using MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). 
 
3. Evaluate the effect of individual treatments of DAC, BIX, and chaetocin on p15, p21, and E-
cadherin gene expression using real time PCR. 
 
4. Develop combinatorial treatments of DAC, BIX, and chaetocin that lead to re-expression of 
p15, p21, and E-cadherin genes in acute myeloid leukemia. 
 
5. Determine changes in DNA methylation and histone 3 lysine 9 di- and tri-methylation 
associated with p15, p21 and E-cadherin promoters using chromatin immunoprecipitation 
assays.  
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4. MATERIALS AND METHODS 
 
4.1 Reagents and suppliers 
The reagents and commercially available kits used in this study are listed in Table 4.1. and 
4.2., respectively. All reagents used for experiments were molecular biology or reagent grade. 
 
Table 4.1. List of reagents and suppliers used in this study 
Reagent Supplier Name 
100 bp DNA ladder Fermentas 
5-aza-  Sigma-Aldrich 
Acetic acid  EMD Chemicals 
Agarose Invitrogen Life Technologies 
Aprotinin Sigma-Aldrich 
BIX-01294 Sigma-Aldrich 
Boric acid EMD Chemicals 
Chaetocin Sigma-Aldrich 
dATP Fermentas 
dCTP Fermentas 
dGTP Fermentas 
DMSO Sigma-Aldrich 
dTTP Fermentas 
Ethanol EMD Chemicals 
Ethidium bromide Invitrogen Life Technologies 
Fetal bovine serum Invitrogen Life Technologies 
Formaldehyde BDH 
GM-CFS R&D Systems 
GlycoBlue coprecipitant Ambion 
HCl EMD Chemicals 
HotStarTaq Polymerase Qiagen 
IL-3 R&D Systems 
IMDM Invitrogen Life Technologies 
Isopropanol EMD Chemicals 
Loading dye 6X solution Fermentas 
Methanol BDH 
MgCl
2
 Qiagen 
MTT reagent Sigma-Aldrich 
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NaOH BDH 
Nuclease free water Qiagen 
PCR buffer 10X Qiagen 
Penecillin/Sterptomycin 100X mix Invitrogen Life Technologies 
Pepstatin A Sigma-Aldrich 
Phenol:chloroform:isoamyl alcohol Ambion 
PMSF Sigma-Aldrich 
Power SYBR green PCR master mix 10X Applied Biosystems 
Propidium iodide Sigma-Aldrich 
Proteinase K Qiagen 
RNAse Worthington 
RNasin Promega 
RPMI Invitrogen Life Technologies 
Salmon sperm DNA/protein A Agarose Millipore 
SDS Promega 
Sodium azide Sigma 
Sodium bicarbonate BDH 
Sodium borate EMD Chemicals 
Trypan blue Invitrogen Life Technologies 
 
 
Table 4.2. Comercially available kits used in this study 
Kits Company 
DNeasy Blood and Tissue Kit Qiagen 
EZ DNA Methylation Kit Cedarlane 
iScript cDNA Synthesis Kit Bio-Rad 
RNeasy MinElute Cleanup Kit Qiagen 
 
 
4.2 Oligonucleotides 
Table 4.3 lists primers and their optimal annealing temperature. PCR, Real-time PCR, and 
methylated PCR primers were purchased from Integrated DNA technologies (IDT). 
Pyrosequencing DNA primers were purchased from EpigenDex and IDT. 
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Table 4.3. Sequences and optimal annealing temperatures of primers used in this study 
Name Sequence Annealing 
temperature 
E-cadherin-PCR-F 
E-cadherin-PCR-R 
E-cadherin-qRT-F 
E-cadherin-qRT-R 
E-cadherin-ChIP-F 
E-cadherin-ChIP-R 
E-cadherin-MSP-M-F 
E-cadherin-MSP-M-R 
E-cadherin-MSP-U-F 
E-cadherin-MSP-U-R 
GAPDH- PCR-F 
GAPDH-PCR-R 
HPRT-qRT-F 
HPRT-qRT-R 
p15-PCR-F 
p15-PCR-R 
p15-qRT-F 
p15-qRT-R 
p15-ChIP-F 
p15-ChIP-R 
p15-MSP-M-F 
p15-MSP-M-R 
p15-MSP-U-F 
p15-MSP-U-R 
p21-PCR-F 
p21-PCR-R 
p21-qRT-F 
p21-qRT-R 
5'-CCTGGGACTCCACCTACAGA-3' 
5'-GGATGACACAGCGTGAGAGA-3' 
5'-AAGAAGCTGGCTGACATGTACGGA-3' 
5'-CCACCAGCAACGTGATTTCTGCAT-3' 
5'-AGAGGGTCACCGCGTCTATG-3' 
5'-CTCACAGGTGCTTTGCAGTT-3' 
5'-TTAGGTTAGAGGGTTATCGCGT-3' 
5'-TAACTAAAAATTCACCTACCGAC-3' 
5'-TAATTTTAGGTTAGAGGGTTATTGT-3' 
5'-CACAACCAATCAACAACACA-3' 
5'-AAGTGAAGGTCGGAGTCAAC-3' 
5'-ATGACAAGCTTCCCGTTCTC-3' 
5'-TGGCGTCGTGATTAGTGATG-3' 
5'-GCACACAGAGGGCTACAATG-3' 
5'-ATGCGCGAGGAGAACAAGGG-3' 
5'-GTACCCTGCAACGTCGCGGT-3' 
5'-AAGCTGAGCCCAGGTCTCCAT-3' 
5'-CCACCGTTGGCCGTAAAC-3' 
5'- GCAGGCTTCCCCGCCCTCGTGACGC-3' 
5'- ATTACCCTCCCGTCGTCCTTCTGC-3' 
5'-GCGTTCGTATTTTGCGGTT-3' 
5'-CGTACAATAACCGAACGACCGA-3' 
5'-TGTGATGTGTTTGTATTTTGTGGTT-3' 
5'-CCATACAATAACCAAACAACCAA-3' 
5'-ATGTCAGAACCGGCTGGGGA-3' 
5'-AGCCTGCTCCCCTGAGCGAG-3' 
5'-CTGGAGACTCTCAGGGTCGAA-3' 
5'-GGCGTTTGGAGTGGTAGAAATCT-3' 
55°C 
 
60°C 
 
61°C 
 
57°C 
 
55°C 
 
59°C 
 
60°C 
 
63°C 
 
58°C 
 
60°C 
 
60°C 
 
60°C 
 
61°C 
 
58°C 
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p21-ChIP-F 
p21-ChIP-R 
p21-MSP-M-F 
p21-MSP-M-R 
p21-MSP-U-F 
p21-MSP-U-R 
5'-GTGGCTCTGATTGGCTTTCTG-3' 
5'-CTGAAAACAGGCAGCCCAAG-3' 
5'-TTTCGGGGAGGGCGGTTTCGGGCGGCGCGG-3' 
5'-CGATACCTCGACGAATCCGC-3' 
5'-GGTGGTGTGGTGGGTTGAGT-3' 
5'-ACAAATCCACACCCAACTCC-3' 
59°C 
 
67°C 
 
62°C 
 
 
 
4.3 Antibodies 
Antibodies used in this thesis are listed in Table 4.4. 
 
Table 4.4. Antibodies used in chromatin immunoprecipitation Assays 
Antibody Supplier Name Catalog Number 
Anti-Histone H3 Millipore 06-755 
Normal mouse IgG Millipore 12-371 
Normal rabbit IgG Millipore 12-370 
MsmAb Histone H3 dimethyl K9 Abcam Ab1220 
RbpAb Histone H3 trimethyl K9 Abcam Ab8898 
 
 
4.4 Cell lines and culture conditions 
Human AML cell lines, Kasumi, KG-1a, and AML193 were purchased from DSMZ 
(Braunschweig, Germany). AML-
medium (IMDM) with 20% (v/v) fetal bovine serum (FBS, Invitrogen) supplemented with 2 
ng/mL human granulocyte macrophage colony stimulating factor (GM-CSF) and 3 units/mL 
human Interleukin-3 (IL-3) (R&D Systems). KG-1a cells were cultured in IMDM with 20% 
(v/v) FBS and Kasumi cells were maintained in RPMI with 10% (v/v) FBS. All cultures 
contained 1% (v/v) penicillin/streptomycin (Gibco) and were maintained at 37°C and 5% CO
2
. 
Culture media was obtained from Invitrogen.  
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4.5. Drug treatments 
For cell proliferation assays, cells were treated with different doses of DAC, BIX-01294, 
and chaetocin either alone or in combination for 72 hours. DMSO or an equivalent volume of 
50:50 acetic acid/water was used as vehicle control. For gene expression analysis using drugs 
alone, a dose response assay of DAC, BIX-01294, and chaetocin was performed in AML cell 
lines for 72 hours. For gene expression analysis using drugs in combination, AML-193 cells 
were treated with 1 µM or 8 µM DAC, 4 µM BIX-01294 and 100 nM chaetocin. Kasumi and 
KG-1a  cells were  treated with  4 µM DAC,  4 µM BIX-01294, and 100 nM chaetocin for 72 
hours. Concentration of drugs in combination is described in the appropriate figure(s). 
  
4.6. Molecular techniques 
 
4.6.1. DNA extraction from AML cells 
Genomic DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) according to 
5 x 10
6
 cells. Concentration and purity of DNA was 
determined by standard A
260
/A
280
 spectrophotometric reading. DNA samples were stored at -
20°C until needed. 
 
4.6.2. RNA extraction from AML cells 
Total RNA was isolated using TRIzol (Invitrogen). Cells were lysed and harvested to a 
concentration of 1 mL trizol for each 5-10 x 10
6
 cells. 4-bromo-2-chlorophenol (BCP) (200 µL) 
was subsequent added to each harvested sample and mixed thoroughly by vortexing. Samples 
were incubated at room temperature for 3 minutes and centrifuged at 12,000 x g for 20 minutes. 
The top, aqueous layer was transferred to a MinElute Cleanup column (Qiagen) and isolated 
RNA was then cleaned using the RNeasy MinElute Cleanup Kit (Qiagen) as described in 
ellets  were  dissolved  in  20  µL  of  nuclease-free water 
(Qiagen) and concentration and purity was determined by standard A
260
/A
280
 
spectrophotometric reading. RNA samples were stored at -80°C until needed. 
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4.6.3. Reverse transcriptase polymerase chain reaction (RT-PCR)  
Complementary  DNA  (cDNA)  was  synthesized  from  1  µg  total  RNA  using  the  iScript 
cDNA Synthesis kit (Bio-Rad). Briefly, 1 µg of total RNA was added to a mix containing 4 µL 
5X  iScript Reaction Mix and 1 µL  iScript Reverse Transcriptase  in a  final volume of 20 µL. 
cDNA was synthesized by incubating the reaction at  25°C for 5 minutes, 42°C for 30 minutes, 
and 85°C  for 5 minutes. Samples were used  for PCR and Real-Time PCR or stored at -20°C 
until needed.  
PCR was  performed  in  50  µL  reaction mixture  containing  1.0  µL  of  cDNA,  1X  buffer 
(Qiagen), 0.2 mM of each dNTP (Fermentas), 0.2 µM of each primers,  and 1.5 U of HotStar 
Taq Polymerase  (Qiagen).  Reactions  were  run  at  95°C  for  15  minutes  followed  by  35 
amplification  cycles  (95°C  for  1  minute,  annealing  Temperature  1  minutes  and  72°C  for  1 
minute)  and  final  incubation  at  72°C  for  10  minutes.  Primer  sequences  and  annealing 
temperatures are presented in Table 4.3. 
 
4.6.4. Agarose gel electrophoresis 
For visualization of DNA, samples were mixed with loading dye 6X solution (Fermentas) 
and resolved in 2% (w/v) agarose gel containing 0.5 µg/mL ethidium bromide and  run at 150 V 
for 30 to 40 minutes using 1X of sodium borate buffer. Visualization and photography was 
done by using the UV light transilluminator GeL Doc (BioRad). 
 
4.6.5. Real-time PCR 
Amplification of cDNA was performed in a 10 µL reaction containing 5 µL Power SYBR 
green PCR master mix (Applied Biosystems), 0.45 µM of each primer and 0.2 µg cDNA using 
a StepOnePlus Real-Time PCR system (Applied Biosystems). Amplification consisted of 1 
cycle at 95°C for 10 minutes and 40 cycles at 95°C and annealing temperature for 50 seconds. 
Hypoxanthine-guanine phosphoribosyltransferase was used as housekeeping gene to normalize 
the StepOnePlus Analysis manual and by Livak and Schmittgen, 2001. 
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4.7. DNA methylation analysis 
 
4.7.1. Sodium bisulfite modification 
Genomic DNA was treated with sodium bisulfite reagent, which converts unmethylated 
cytosine to uracil (Figure 4.1), and eventually thymidine following PCR. This procedure 
allowed us to distinguish between methylated and unmethylated cytosine and was performed 
using the EZ DNA methylation kit (Cedarlane). In this procedure, 2 µg of genomic DNA was 
perform methylation specific PCR and pyrosequencing analysis or were stored at -20°C.  
 
 
 
 
Figure 4.1. Schematic representation of the chemical conversion of cytosine to uracyl. The 
bisulfite mediated deamination of cytosine proceeds by three steps in an acid-catalized reaction. 
The first step is a reversible addition of HSO
3
-
 to cytosine. Second step, is the liberation of NH
3
 
by hydrolysis and third step is the release of HSO
3
-
 to regenerate the 5,6-doble bond, forming 
uracyl (Hayatsu, 2008). dR, deoxyribose. 
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4.7.2. Methylation specific PCR (MSP) 
DNA methylation within the CpG islands of the p15, p21, and E-cadherin promoters was 
determined using methylation-specific PCR after sodium bisulfite treatment of genomic DNA 
as mentioned above. PCR was performed in a 50 µL final volume reaction containing 1 µL of 
modified DNA, 1X PCR buffer (Qiagen), 2.5 mM MgCl
2
, 0.4 mM of each dNTP, 0.2 µM of 
each primer set (methylated or unmethylated set) and 1 U of HotStar Taq Polymerase (Qiagen). 
PCR reaction was performed at 95°C for 15 minutes followed by 35 amplification cycles (95°C 
1minute, annealing temperature for 1 minute, and 72°C for 1.5 minutes) and a final elongation 
step at 72°C for 10 minutes. Methylation specific PCR primers were described previously  by 
Scott, et al 2007 and Lakshmikuttyamma et al., 2010. Primer sequences and annealing 
temperatures are listed in Table 4.3. Modified DNA from HeLa and HL-60 cells were used as 
unmethylated MSP positive control for E-cadherin and p15 genes, respectively. 
 
4.7.3 Pyrosequencing 
Sodium bisulfite treated genomic DNA was PCR-amplified using the MSP PCR method 
as described above. PCR products were then sequenced to determine levels of CpG island 
methylation within the p15, p21 and E-cadherin gene promoters using pyrosequencing 
analaysis. Pyrosequence was performed by EpigenDX (USA).  
Briefly, pyrosequencing employs a cascade enzyme system (Polymerase, Sulfurylase, 
Luciferase and Apyrase enzymes) that generates light for every incorporated nucleotide that 
form a pair with the complementary base in the DNA strand. The intensity of light (measured as 
peak heights) is proportional to the number of nucleotide molecules incorporated (for example 
if two sequential TT are incorporated it will be shown as a higher peak than a single T and same 
for double or single G, C or A). By pyrosequencing, unmethylated cytosine is measured as the 
relative content of T (see sodium bisulfite conversion above) at the CpG site and methylated 
cytosine, is measured as the relative content of C at the CpG site (appearing as TC at each CpG 
site).  
 
The degree of methylation is calculated by the QCpG software, where it compares the 
generated pyrogram (pyrosequencing- chromatogram) to the theoretical histogram (Figure 4.2) 
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and then calculates the percentage methylation (%C) from the ratio of C/T as follows 
(EpigenDX, 2010): 
 
                 % C =             C peak height x 100                 
                               C peak height + T peak height  
 
 
4.8. Cell cycle  
Cell cycle analysis was performed using the propidium iodide staining method. AML cells were 
treated with DAC, BIX-01294, or chaetocin for 72 hours and 1.5 x 10
6
 cells were harvested and 
washed in ice cold 1X PBA (1X PBS, 0.1% (w/v) bovine serum albumin, 0.02% (w/v) sodium 
azide).  Cells  were  fixed  in  ice  cold  ethanol  and  incubated  overnight  at  4°C  for  pellet 
precipitation. Cell pellets were reconstituted in Triton-PBA [0.1% (v/v) Triton X-100 and 1X 
PBA] for 5 minutes, pelleted by centrifugation, and resuspended in 500 units/mL RNAse 
working  solution  (Worthington)  at  37°C  for  30  minutes.  Following  by  cell  staining  in 
propidium iodide working solution (0.05 mg/mL PI in PBA; Sigma) at room temperature in the 
dark  for  15  minutes  and  filtered  through  35µm  nylon  mesh.  Samples  were  run  in a Flow 
cytometer (Coulter Epics XL) and analyzed using the FloJo software (Tree Star, Inc). 
 
4.9. MTT spectrophotometric assay 
Cell proliferation and cytotoxicity was measured by MTT assay. Cells were plated in 
triplicate at 2 x 10
5
 cells per well in a 96 well plate and treated with a vehicle control and 
different doses of DAC, BIX, and chaetocin for 72 hours. After treatment 1/10 culture volume 
of 5 mg/mL MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
(Sigma-Aldrich) was added and incubated for 4 hours at 37°C to allow formation of formazan 
crystals.  The  resulting  crystal  were  solubilized  by  adding  100  µL  of  solubilization  solution 
(10%  (v/v)  SDS  and  0.01  M  HCl)  to  each  well  and  incubating  at  37°C  overnight. 
Spectrophotometric absorbance reading was taken at 570 nm with 650 nm background 
subtraction using a Spectcramax 340 PC plate reader (Molecular Devices).  
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Figure 4.2. Pyrosequencing analysis of CpG methylation. An example of pyrosequencing 
analysis at 3 CpG sites (gray columns) showing a theoretical histogram (a) and the pyrogram 
generated (b). The theoretical histogram (a) indicates the number of nucleotides incorporated in 
the Y-axis at each nucleotide dispensation in the X-axis (the sequence around the analyzed C/T 
plus some control bases). In the histogram, the dark brown bars represent the nucleotide 
positions conserved between alleles and arrow empty bars portray the number of nucleotides 
incorporated. The pyrogram (b) represents the sequential nucleotide dispensations (X-axis) 
plotted against the resultant measured light intensity (Y-axis). The sequence analyzed is shown 
above the pyrogram under FI1 name, where Y represents the potential methylated cytosine in 
the CpG. In the pyrogram, E and S (X-axis) denote the addition of the enzyme and substrate, 
respectively. The A dispensation at position 1, T at position 5, and A at position 17, represent 
negative controls (used as internal control for pyrosequencing reaction). In the template 
sequence [GGTYGYGTTGAGTTGYGTTA ], identical following nucleotides (underlying) 
result in higher peak heights, such as G at position 2 that contains signal for (GG), T at position 
11, position 16, and position 22 for (TT). Each T (highlighted) proceeding a CpG site (denotes 
as Y) is counted as unmethylated cytosine (T) in the CpG. In both figures, light yellow columns 
indicate control regions for completion of bisulfite treatment represented as C at position 10 and 
15.  Percentage methylation is calculating by the QCpG software (C% = C peak/(Cpeak + T 
peak)). For example, in the first analyzed CpG (first gray column) C peak = 125 and T peak = 
(470/2) = 235. Then, C%= 35%.   
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4.10. Chromatin immunoprecipitation (ChIP) assay 
ChIP assays were performed based on the Upstate ChIP assay protocol (Upstate 
biotechnology). Modifications to the protocol were made. Briefly, Cells were collected and 
resuspended in 10 mL growth medium containing 1% formaldehyde and incubated at room 
temperature for 10 minutes. The cross-link reaction was stopped by adding 1 mL of 1.25 M 
Glycine. Cells were washed with cold 1X PBS and lysed in 600 µL SDS lysis buffer (1% (v/v) 
SDS, 10 mM EDTA, 50 mM Tris at pH 8.0) supplemented with protease inhibitors (1 mM 
PMSF, 1 µg/mL aprotinin, 1 µg/mL pepstatin A). Genomic DNA was sheared to a size of 200-
1000 bp using a Branson Sonifier 450 sonicator (output control of 1.5, 60% duty cycle). 
Sheared lysates were cleared by centrifugation and split into fractions, Input fraction, positive 
antibody fraction (5 µg  specific  antibody)  and  negative  antibody  fraction  (5  µg  IgG). 
Immunoprecipitation was performed at 4°C overnight.  
Cross-linked protein/DNA samples were reversed by heating and genomic DNA was 
isolated by proteinase K digestion, phenol:chloroform extraction (Ambion), and ethanol 
precipitation with the assistance of 30 µg GlycoBlue coprecipitant (Ambion). DNA pellets were 
dissolved in 20 µL nuclease free water and used for Real-Time PCR or stored at -20°C. 
 
4.11. Statistical analysis 
Differences between control (untreated cells) and drug treatments (treated cells) were assessed 
using the 2-sided t test. The significance levels were set at p < 0.05 (*) and p < 0.01 (**). 
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5. RESULTS 
  
5.1. p15, p21, and E-cadherin promoter silencing in AML cell lines 
 
5.1.1. Analysis of p15, p21, and E-cadherin expression and promoter methylation in AML 
cell lines 
In cancer, genes that encode for cyclin-dependent kinase inhibitors (CDKI) and cadherin 
proteins (CDH) are frequently deregulated, leading to inactivation of growth inhibitory signals, 
excessive proliferation of malignant cells, and metastasis (Corn et al., 2000; Melki et al, 2000; 
Malumbres and Barbacid, 2009). p15, p21, and E-cadherin genes have been reported to be 
epigenetically silenced in a variety of AML cell lines and patients and more importantly, it has 
been suggested that loss of function of these genes is correlated with promoter 
hypermethylation (Herman, 1997; Corn et al., 2000; Melki et al, 2000; Scott et al, 2006; 
Lakshmikuttyamma et al., 2010). In order to investigate the p15, p21, and E-cadherin gene 
expression and promoter methylation in AML, three model cell lines were studied: AML-193, 
KG-1a, and Kasumi. p15, p21, and E-cadherin expression were detected by reverse 
transcriptase PCR. Only positive control cell lines HL-60, THP-1, and HeLa expressed p15, 
p21, and E-cadherin genes, respectively (Figure 5.1). 
 Promoter methylation was analyzed using two techniques: methylation-specific PCR 
(MSP) and DNA pyrosequencing (explanation of analysis in Figure 4.2). Methylated and 
unmethylated cytosines levels within CpG islands were measured using DNA bisulfite 
modification in both assays. Bisulfite converts unmethylated cytosines to uracil and 
subsequently to thymidine after PCR amplification. MSP analysis of p15 and E-cadherin 
promoter regions detected only the presence of methylated alleles in AML-193, KG-1a, and 
Kasumi cell lines (Figure 5.3a and Figure 5.3b). MSP analysis of the p21 promoter region 
detected only unmethylated alleles in AML cell lines tested (Figure 5.3c). To confirm p15, p21, 
and E-cadherin MSP results and to quantify the degree of promoter methylation, DNA 
pyrosequencing was performed. Pyrosequencing results correlated with MSP data and revealed 
that cytosines present as CpGs within regions of p15 and E-cadherin promoters were heavily 
methylated in AML cell lines studied (Figure 5.4 and Figure 5.5). In contrast, the cytosines 
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present as CpGs in regions of the p21 promoter that were analyzed were completely 
unmethylated in AML-193 and Kasumi cell lines (Figure 5.6).  
 
 
 
 
Figure 5.1. p15, p21, and E-cadherin expression in AML cell lines. p15, p21 and E-cadherin 
gene expression in AML cell lines was analyzed using reverse transcriptase PCR. GAPDH 
expression levels were used as cDNA input controls. HL-60, THP-1, and HeLa cell lines were 
used as positive control expression for p15, p21, and E-cadherin, respectively. 
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Figure 5.2. p15, p21, and E-cadherin MSP and ChIP PCR product location. Illustrated are the 
CpG island associated promoter region of the p15 (a) E-cadherin (b) and p21 (c) genes. CpG 
islands for p15 (chr9:21998658-21999471), p21 (chr6:36754223-36754715) and E-cadherin 
(chr16:67328536-67329145) were identified using UCSC genome browser 
(http://genome.ucsc.edu). PCR primer locations are indicated by arrows. The scale represents 
the distance from the transcription start site. 
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Figure 5.3. p15, E-cadherin, and p21 promoter methylation in AML cell lines. MSP analysis of 
p15 (a), E-cadherin (b), and p21 (c) promoter methylation. U and M indicate PCR amplicons 
generated using primers specific for unmethylated and methylated p15, p21, and E-cadherin 
promoter alleles, respectively.  
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AML-193 
% Methylation: 90.3; SD: 13.7 
 
KG-1a 
% Methylation: 92.3; SD: 13.1 
 
Kasumi  
% Methylation: 88.5; SD: 13.7 
 
Figure 5.4. DNA pyrosequencing analysis of p15 promoter methylation in AML cell lines. 
Percentage methylation is the mean methylation of CpGs in the p15 promoter. SD, represents 
the standard deviation of the percentage mean methylation. The sequence analyzed is shown 
above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars highlight the peaks resulting from sequential dispensations of C and T 
from which methylation is assessed. Pyrosequencing output then indicates the methylation 
percentage calculated from the ratio of the peaks heights of C and T (underlying TC and blue 
circles) in the analyzed CpG positions (first grey bar). Blue and red colours represent the 
confidence of the sequence pattern matches: greater than 90 percent and less than 70 percent, 
respectively.  
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AML-193  
% Methylation: 96.9; SD: 3.4 
 
KG-1a 
% Methylation: 82.1; SD: 12.3  
 
Kasumi 
% Methylation: 96.5; SD: 3.3 
 
Figure 5.5. DNA pyrosequencing analysis of E-cadherin promoter methylation in AML cell 
lines. Percentage methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, 
represents the standard deviation of the percentage mean methylation. The sequence analyzed is 
shown above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue, yellow and red colours represent the 
confidence of the sequence pattern matches: greater than 90 percent, 70-89 percent and less 
than 70 percent, respectively.  
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AML-193 
% Methylation: 2.9; SD: 1,2 
a) Region1 (CpG No 8-21) 
 
b) Region 2 (CpG No 22-24) 
 
c) Region 3 (CpG No 25-31) 
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Kasumi- p-21 
% Methylation: 2.8; SD: 1.5 
d) Region1 (CpG No 8-21) 
 
e) Region 2 (CpG No 22-24) 
 
f) Region 3 (CpG No 25-31) 
 
Figure 5.6.  Continued. DNA pyrosequencing analysis of p21 promoter methylation in AML-
193 and Kasumi cell lines. Percentage methylation is the mean methylation of CpGs in p21 
promoter. SD, represents the standard deviation of the percentage mean methylation. (a), (b) 
and (c) indicate 3 different regions analyzed at the p21 promoter in AML-193 cells. (d), (e) and 
(f) indicate regions analyzed at the p21 promoter in Kasumi cells. The sequence analyzed is 
shown above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue, yellow and red colours represent the 
confidence of the sequence pattern matches: greater than 90 percent, 70-89 percent and less 
than 70 percent, respectively. 
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5.2. The effect of DAC, BIX, and chaetocin on AML cell proliferation  
To determine whether epigenetic inhibitors DAC, BIX, and chaetocin can induce re-
expression of epigenetically silenced genes in AML, we first measured the effects of these 
drugs on AML cells proliferation using the MTT assay. The MTT assay colorimetrically 
quantifies the effect of these drugs on AML cell proliferation by measuring mitochondrial 
enzyme activity based on the reduction of MTT to formazan, which produces a colour change 
from yellow to purple. The mitochondrial enzymes that catalyze the reaction are only active 
when a cell is viable, allowing the correlation between viability and spectrophotometric 
readings (Carmichael et al., 1987).  
Previous work in our lab established that DAC does not affect AML cell viability at doses 
up to 16 µM  (Geyer et al., unpublished). Therefore, we evaluated the effect of BIX and 
chaetocin on AML-193, KG-1a, and Kasumi cell viability. AML-193, KG-1a, and Kasumi cell 
lines were treated for 72 hours with different doses of BIX and chaetocin and then analyzed 
using the MTT assay. Both BIX and chaetocin treatment reduce AML cell viability as shown in 
Figure 5.7. Chaetocin was the most toxic drug to AML-193, KG-1a, and Kasumi cell lines, 
causing a dramatic decrease on cell viability at doses above 100 nM, 20 nM, and 50 nM, 
respectively (Figure 5.7).  
Since DAC has little effect on cell viability it was added to AML cells treated with BIX and 
chaetocin in order to analyze its ability to potentiate the anti-proliferative effects of BIX and 
chaetocin. The effect of chaetocin and BIX on AML cell proliferation was greater when DAC 
was used in combination with these two drugs (Figure 5.7). Furthermore, decreases in cell 
proliferation observed with BIX and chaetocin were consistent with changes in the cell cycle 
profile. BIX decreased the population of cells in the dividing phase (S phase) and G2/M and 
increased the population in G1 phase, which contains check points control for cell cycle arrest 
(Figure 5.8). Similarly, chaetocin induced changes on cell cycle, increasing the population in 
subG1 and decreasing the population of dividing cells (S - G2/M) (Figure 5.9).  
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a) 
 
b) 
 
c) 
 
 
Figure 5.7. Proliferation of AML cell lines treated with BIX and chaetocin. AML-193 (a), KG-
1a (b), and Kasumi (c) cell lines were treated for 72 hours with indicated concentrations of 
BIX-01294 (BIX) and chaetocin in presence (BIX+DAC and chaetocin+DAC) or absence 
(BIX-DAC and chaetocin-DAC) of DAC (1 µM). Samples were analyzed using the MTT assay. 
The data is represented as percentage (%) relative proliferation, which is based on the 
proliferation normalized to the untreated cells (100% proliferation). Error bars represent 
standard deviation from three independent experiments.  
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Figure 5.8. Effect of BIX-01294 on the cell cycle in AML cell lines. Cell cycle histograms 
represent the propidium iodide (PI) staining of DNA content  in different phases of the cell 
cycle before and after treatment with BIX. AML-193, KG-1a, and Kasumi cells were treated for 
72 hours with either BIX (4 µM) or vehicle control (DMSO). The percentage of cells  in each 
phase of the cell cycle is shown on the histograms. At 4 µM dose, BIX increased the number of 
cells undergoing G1 phase but does not cause cell apoptosis.Cell cycle analysis was performed 
with the Watson algorithm using the FloJo software. 
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Figure 5.9. Effect of chaetocin on the cell cycle in AML cell lines. Cell cycle histograms 
represent the propidium iodide (PI) staining of DNA content in different phases of the cell cycle 
before and after treatment with chaetocin. AML-193 and KG-1a cells were treated for 72 hours 
with either chaetocin (100 nM) or vehicle control (DMSO). The percentage of cells in each 
phase of the cell cycle is shown on the histograms. At 100 nM dose, chaetocin increased the 
number of cells undergoing apoptosis. Cell cycle analysis was performed with the Watson 
algorithm using the FloJo software. 
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5.3. Effect of DAC on p15, p21, and E-cadherin gene expression 
5.3.1. DAC-induced expression of p15, p21, and E-cadherin genes 
DAC has been extensively used in cancer epigenetic therapy for inducing expression of 
genes that are silenced by promoter hypermethylation in various types of cancer (Hellebrekers 
et al., 2007; Jain et al., 2009). Moreover, DAC has also been recognized to induce expression 
of genes without promoter methylation, which is the case of p21 gene in this study (Zhu and 
Otterson, 2003; McGarvey et al., 2006). In order to investigate epigenetic changes that lead to 
re-activation of tumor suppressor genes in AML, we evaluated the effect of DAC, BIX, and 
chaetocin on p15, p21, and E-cadherin gene re-expression in AML cell lines.  
To optimize concentrations of DAC that leads to gene re-activation, AML-193, KG-1a, and 
Kasumi cell lines were treated with DAC in a dose response induction manner and p15, p21 and 
E-cadherin expression were analyzed by real time PCR. DAC significantly induced expression 
of  p15  at  doses  higher  than  1  µM  in  AML-193  and  4  µM  in  KG-1a and Kasumi cell lines 
(Figure 5.10a). Similarly, in KG-1a and Kasumi cells, E-cadherin expression was induced with 
4 µM DAC, whereas 8 µM DAC was required to induce E-cadherin expression in the AML-193 
cell line (Figure 5.10b). Despite the p21 promoter being unmethylated, DAC induced 
expression of p21 in all AML cell lines studied. Significant p21 expression was observed in 
AML-193, KG-1a, and Kasumi cell lines after treatment with 4 µM DAC (Figure 5.10c).  
 
5.3.2. DAC-induced p15 and E-cadherin expression by reducing promoter methylation 
Based on the ability of DAC to induce expression of hypermethylated p15 and E-cadherin 
genes in AML cell lines, we measured the effect of DAC on promoter demethylation using 
DNA pyrosequencing. Since treatment of KG-1a  and  Kasumi  cells  with  4  µM  DAC 
significantly increased p15 and E-cadherin gene expression, we chose only Kasumi and AML-
193 cell lines to analyze promoter demethylation. Treatment of AML-193 with 1 µM DAC and 
Kasumi with 4 µM DAC  resulted  in  a decrease of p15 and E-cadherin promoter methylation 
across the region of the CpG island analyzed. The mean level of p15 and E-cadherin promoter 
methylation was reduced on the order of 30% in all AML cell lines studied (Figure 5.11, Figure 
5.12, Figure 5.13, and Figure 5.14). In the unmethylated p21 promoter, pyrosequencing results 
revealed that the level of CpG island methylation did not change, which was in agreement with 
previous MSP and pyrosequencing results (Figure 5.15 and Figure 5.16).   
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Figure 5.10. Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell lines. 
AML-193, KG-1a, and Kasumi cell lines were treated with different doses of DAC for 72 
hours. P15 (a), E-cadherin (b), and p21(c) expression was analyzed using HPRT as endogenous 
control gene. Error bars represents standard deviation of three independent experiments and (*) 
represents P-value < 0.05 and (**) represent P-value <0.01 between treated and untreated cells. 
Control represents the untreated cells. 
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a) Control 
% Methylation: 95.1%; SD: 8.0  
 
b) 1 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
 
Figure 5.11. Effect of DAC on p15 promoter methylation in AML-193 cell line. Cells were 
untreated (a) or treated (b) for 72 hours with the indicated concentration of DAC. Percentage 
methylation is the mean methylation of CpGs in the p15 promoter. SD, represents the standard 
deviation of the percentage mean methylation. The sequence analyzed is shown above each 
pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, the Y-
axis represents the signal intensity (arbitrary units), which is proportional to the number of 
nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue and yellow colors represent the confidence of the sequence 
pattern matches: greater than 90% and between 70-89%, respectively.  
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a)  Control 
% Methylation: 95%; SD: 4.9 
 
 
b) 4 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
 
Figure 5.12. Effect of DAC on p15 promoter methylation in Kasumi cell line. Cells were 
untreated (a) or treated (b) for 72 hours with the indicated concentration of DAC. Percentage 
methylation is the mean methylation of CpGs in the p15 promoter. SD, represents the standard 
deviation of the percentage mean methylation. The sequence analyzed is shown above each 
pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, the Y-
axis represents the signal intensity (arbitrary units), which is proportional to the number of 
nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue color represents the confidence of the sequence pattern 
matches greater than 90 percent. 
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a) Control  
% Methylation: 95.5; SD:4.7 
 
b) 8 µM DAC 
% Methylation: 66.8; SD: 7.0 
 
Figure 5.13. Effect of DAC on E-cadherin promoter methylation in the AML-193 cell line. 
Cells were untreated (a) or treated (b) for 72 hours with the indicated concentration of DAC. 
Percentage methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, 
represents the standard deviation of the percentage mean methylation. The sequence analyzed is 
shown above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue, yellow and red colours represent the 
confidence of the sequence pattern matches: greater than 90 percent, 70-89 percent and less 
than 70 percent, respectively. 
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a) Control 
% Methylation: 90.1; SD: 9.0 
 
b) 4 µM DAC 
% Methylation: 55.8; SD: 9.2  
 
 
Figure 5.14. Effect of DAC on E-cadherin promoter methylation in Kasumi cell line. Cells 
were untreated (a) or treated (b) for 72 hours with the indicated concentration of DAC. 
Percentage methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, 
represents the standard deviation of the percentage mean methylation. The sequence analyzed is 
shown above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue, yellow and red colours represent the 
confidence of the sequence pattern matches: greater than 90 percent, 70-89 percent and less 
than 70 percent, respectively. 
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AML-193, Control  
 
a) Region1 (CpG No 8-21) 
% Methylation: 3.4; SD: 1.08 
 
 
b) Region 2 (CpG No 22-24) 
% Methylation: 1.9; SD: 0.34  
 
 
c) Region 3 (CpG No 25-31) 
% Methylation: 1.7; SD: 1.26 
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AML-193, 1 µM DAC 
 
a) Region1 (CpG No 8-21) 
% Methylation: 2.5; SD: 1.06 
 
 
b) Region 2 (CpG No 22-24) 
% Methylation: 2.5; SD: 0.91  
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c) Region 3 (CpG No 25-31) 
% Methylation: 2.4; SD: 0.87 
 
 
Figure 5.15. Effect of DAC on p21 promoter methylation in AML-193 cell line. AML-193 
cells were untreated (Control) or treated (1µM DAC) for 72 hours with the indicated 
concentration of DAC. (a), (b) and (c) represent the analyzed CpG regions in the p21 promoter. 
Percentage methylation is the mean methylation of CpGs in the p21 promoter. SD, represents 
the standard deviation of the percentage mean methylation. The sequence analyzed is shown 
above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue and yellow colours represent the 
confidence of the sequence pattern matches: greater than 90 percent and between 70-89 percent, 
respectively. 
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Kasumi, Control 
 
a) Region 1 (CpG No 8-21) 
% Methylation: 2.9; SD: 1.04 
 
 
b) Region 2 (CpG No 22-24) 
% Methylation: 1.6; SD: 1.53 
 
 
b) Region 3 (CpG No 25-31) 
% Methylation: 2.6; SD: 2.03 
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Kasumi, 4 µM DAC 
 
 
a) Region 1 (CpG No 8-21) 
% Methylation: 2.9; SD: 0.82 
 
 
 
b) Region 2 (CpG No 22-24) 
% Methylation: 3.9; SD: 1.14 
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c) Region 3 (CpG No 25-31) 
% Methylation: 2.8; SD: 1.47 
 
 
Figure 5.16. Effect of DAC on p21 promoter methylation in Kasumi cell line. Cells were 
untreated (Control) or treated (4µM DAC) for 72 hours with the indicated concentration of 
DAC. (a), (b) and (c) represent the analyzed CpG regions in the p21 promoter. Percentage 
methylation is the mean methylation of CpGs in the p21 promoter. SD, represents the standard 
deviation of the percentage mean methylation. The sequence analyzed is shown above each 
pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, the Y-
axis represents the signal intensity (arbitrary units), which is proportional to the number of 
nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue and yellow colours represent the confidence of the sequence 
pattern matches: greater than 90 percent and between 70-89 percent, respectively. 
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5.3.3. DAC-mediated induction of p15, p21, and E-cadherin correlated with changes in 
H3K9 methylation 
DNA methylation has been recognized to cooperatively interact with histone methylation in 
silencing of gene expression (Esteve et al., 2006; Epztejn-Litman et al., 2008; Dong et al., 
2008). Histone 3 Lysine 9 (H3K9) di- and tri-methylation are common repressive marks present 
in regulatory regions of transcriptional silenced genes (Kouzarides, 2007). Since previous 
studies reported that DAC treatment decreased H3K9 methylation in promoter regions of 
silenced genes (Fahrner et al., 2002; Nguyen et al., 2002; Coombes et al., 2003), we used 
chromatin immunoprecipitation (ChIP) assays to analyze the effect of DAC and other 
epigenetic drugs on p15, p21, and E-cadherin promoter H3K9 methylation (Table 5.1). AML-
193 and Kasumi cells were treated with DAC for 72 hours and protein lysates were subjected to 
chromatin immunoprecipitation using antibodies for anti-dimethyl-H3K9 and anti-trimethyl-
H3K9. DAC decreased both H3K9 di- and tri-methylation levels at p15 and E-cadherin 
promoters relative to the untreated control (Figure 5.17a and Figure 5.17b). H3K9 tri-
methylation levels decreased to a greater extent than H3K9 di-methylation in response to DAC 
treatment in AML-193 and Kasumi cell lines (Figure 5.17a and Figure 5.17b). In contrast, at the 
p21 promoter DAC treatment increased levels of H3K9 di- and tri-methylation in both AML-
193 and Kasumi cell lines (Figure 5.17a and Figure 5.17b). Levels of histone 3 (H3) were also 
measured to analyze the possibility of nucleosome depletion. However, we did not observe 
significant changes in H3 levels, indicating that variations in histone H3K9 di- and tri-
methylation were not due to nucleosome depletion (Figure 5.17c). 
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Table 5.1. Chromatin immunoprecipitation assays of the effect of epigenetic drugs on H3K9 
methylation in AML-193 cell line 
 
 
AML-193 cells were treated or untreated for 72 hours with the indicated concentration of drugs: 
DAC (1µM), BIX (4 µM), and chaetocin (100nM), either alone or as a combinatorial treatment. 
Untreated cells represent the Control treatment. Quantitative real time PCR was performed and 
ChIP results obtained by three independent replicate experiments are represented as fold 
difference between untreated (Control) and treated cells. H3K9Me2 and H3K9Me3 represent 
the di-methylation and tri-methylation levels at Histone 3 lysine 9. Background signal were 
measured with No Antibody (Ab) control and IgG Antibody control and then subtracted from 
signal obtained from the ChIP samples. Changes on H3-core histone were measured to assure 
no nucleosome depletion. SD, represents the standard deviation of three independent 
experiments.  
    
64 
 
 
 
Figure 5.17. Chromatin immunoprecipitation analysis of the effect of DAC on H3K9 di- and 
tri-methylation and H3 associated with p15, E-cadherin, and p21 promoters in AML cell lines. 
(a) ChIP assay using dimethyl-H3K9 (H3K9Me2) antibodies. (b) ChIP assay using trimethyl-
H3K9 (H3K9Me3) antibodies. (c) ChIP assay using H3 (H3) antibodies. AML-193 and Kasumi 
cells were treated for 72 hours with the following concentrations of DAC: AML-193: p15 and 
p21 (1 µM), E-cadherin (8 µM); Kasumi: p15, E-cadherin and p21 (4 µM). Histograms show 
the relative fold expression of PCR products (immunoprecipitated DNA) quantified using real 
time PCR. Error bars represent standard deviation from three independent experiments. ** 
Represents P-values < 0.05 and (**) represent P-value <0.01 between treated and untreated 
cells. Control represents the untreated cells. 
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5.4. Effect of BIX on p15, p21, and E-cadherin gene expression 
 
5.4.1. BIX treatment did not re-activate expression of p15 and E-cadherin genes in AML 
cell lines 
Like DNA methylation, histone methylation is an important epigenetic mark for regulation 
of gene expression (Kouzarides, 2007). Alterations in histone methylation, such as those 
observed at positions H3K9 and H3K27 have been associated with aberrant gene silencing in 
various form of cancer (Ohm et al., 2007; Schlesinger et al., 2007). Moreover, previous studies 
reported that epigenetically silenced genes that are re-activated by DAC treatment still present 
repressive H3K9 methylation marks in their promoter regions (Zhu and Otterson, 2003; 
McGarvey et al., 2006). To evaluate whether inhibition of histone methylatransferase activity 
leads to a changes in H3K9 methylation that might influence re-expression of epigenetically 
silenced genes, we used a specific G9a (dimethyl-H3K9) inhibitor BIX-01294 (BIX). This drug 
was first tested for its ability to re-express p15, p21, and E-cadherin genes in AML cell lines. 
Initially, expression of p15, p21, and E-cadherin was monitored in the presence of various 
concentrations of BIX. AML-193, KG-1a, and Kasumi cells were treated with BIX for 72 hours 
and relative expression was measured by real time PCR. BIX did not significantly induce the 
expression of p15 and E-cadherin at doses up to 4 µM in AML-193 and Kasumi cells and at 
doses  up  to  8  µM  in  the  KG-1a cell line (Figure 5.18a and Figure 5.18b). In contrast, BIX 
induced a significant increase of p21 expression with an increase of 3.5-fold following 
treatment with 4 µM BIX in AML-193 cells. No increase in p21 expression however was 
observed in KG-1a and Kasumi cell lines (Figure 5.18 c). 
 
5.4.2. BIX reduced H3K9 methylation levels at p15, p21, and E-cadherin promoters 
without inducing gene expression 
Although BIX did not significantly induce expression of p15, p21, and E-cadherin in AML 
cell lines (with exception of p21 expression in AML-193 cells), we still determined whether 
BIX decreased H3K9 di- and tri-methylation at p15, p21, and E-cadherin promoters in AML-
193 and Kasumi cell lines. Using ChIP assays with anti-dimethyl-H3K9 and anti-trimethyl-
H3K9 antibodies, we tested the ability of BIX (4 µM) to cause changes in promoter H3K9 di 
and tri-methylation. BIX treatment significantly reduced H3K9 di-methylation levels at p15 
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promoter in AML-193 and Kasumi cell lines (Figure 5.19a). BIX had no effect on H3K9 tri-
methylation at p15 and E-cadherin promoter in any of the cell lines tested (Figure 5.19a and 
Figure 5.19b). However, a decrease in H3K9 di-methylation levels at E-cadherin promoter was 
only observed in Kasumi cells (Figure 5.19a). In contrast, the p21 promoter region was 
associated with reduced levels of H3K9 di- and tri-methylation in AML-193 treated cells 
(Figure 5.19a and Figure 5.19b). No changes were observed in histone H3 levels, indicating that 
changes in H3K9 methylation were not due to nucleosome depletion (Figure 5.19c).  
 
5.4.3. BIX did not induce changes in promoter methylation at p15 and E-cadherin 
promoters 
Previous it has been shown that G9a directly interacts with DNMTs to establish a 
coordinated mechanism for DNA and histone methylation in silencing of genes during cell 
replication (Esteve et al., 2006). In order to evaluate whether BIX induced changes in promoter 
methylation, we analyzed the effect of BIX on p15 and E-cadherin promoter methylation in 
AML-193 and Kasumi cells. Treatment with BIX did not produce any change in the mean of 
p15 and E-cadherin promoter methylation state as determined by DNA pyrosequencing (Figure 
5.20, Figure 5.21, Figure 5.22 and Figure 5.23).  
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Figure 5.18. Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell lines. 
AML-193, KG-1a, and Kasumi cell lines were treated with different doses of BIX for 72 hours. 
p15 (a), E-cadherin (b), and p21(c) gene expression was analyzed using HPRT as endogenous 
control expression. Error bars represents standard deviation of three independent experiments 
and (*) represents P-value < 0.05 between treated and untreated cells. Control represents the 
untreated cells. 
68 
 
 
 
Figure 5.19. Chromatin immunoprecipitation analysis of the effect of BIX on H3K9 di- and tri-
methylation and H3 associated with the p15, E-cadherin, and p21 promoter in AML cell lines. 
(a) ChIP assay of dimethyl-H3K9 (H3K9Me2) antibodies. (b) ChIP assay of trimethyl-H3K9 
(H3K9Me3) antibodies. (c) ChIP assay of H3 (H3) antibodies. AML-193 and Kasumi cells 
were  treated with  BIX  (4  µM)  or  untreated  for  72  hours. Histograms  show  the  relative  fold 
expression of PCR products (immunoprecipitated DNA) quantified using real time PCR. Error 
bars represent standard deviation of three independent experiments. ** Represents P-values < 
0.05 and (**) represent P-value <0.01 between treated and untreated cells. Control represents 
the untreated cells. 
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a) Control  
% Methylation: 90.3; SD: 13.7  
 
b) 4 µM BIX 
% Methylation: 89.8; SD: 13.6 
 
Figure 5.20. Effect of BIX on p15 promoter methylation in AML-193 cell lines. AML-193 
cells were untreated (a) or treated (b) for 72 hours with 4µM BIX. Percentage methylation is the 
mean methylation of CpGs in the p15 promoter. SD, represent the standard deviation of the 
percentage mean methylation. The sequence analyzed is shown above each pyrogram, where Y 
represents the location of the cytosine in the CpG. In the pyrogram, the Y-axis represents the 
signal intensity (arbitrary units), which is proportional to the number of nucleotides 
incorporated (as peaks heights) and the X-axis is the dispensation order. The gray bars indicate 
the CpG positions, where the degree of methylation is assessed from the ratio of the peaks 
heights of C and T. Blue, yellow and red colours represent the confidence of the sequence 
pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, respectively. 
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a) Control 
% Methylation: 88.5; SD: 13.7 
 
 
b) 4 µM BIX 
% Methylation: 88.8; SD: 13.7 
 
Figure 5.21. Effect of BIX on p15 promoter methylation in the Kasumi cell line. Kasumi cells 
were untreated (a) or treated (b) for 72 hours with 4 µM BIX. Percentage methylation is the 
mean methylation of CpGs in the p15 promoter. SD, represent the standard deviation of the 
percentage mean methylation. The sequence analyzed is shown above each pyrogram, where Y 
represents the location of the cytosine in the CpG. In the pyrogram, the Y-axis represents the 
signal intensity (arbitrary units), which is proportional to the number of nucleotides 
incorporated (as peaks heights) and the X-axis is the dispensation order. The gray bars indicate 
the CpG positions, where the degree of methylation is assessed from the ratio of the peaks 
heights of C and T. Blue, yellow and red colours represent the confidence of the sequence 
pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, respectively. 
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a) Control 
 %Methylation: 96.9; SD: 3.4  
 
 
 
b) 4 µM BIX 
% Methylation: 96.4; Sd: 3.3 
 
Figure 5.22. Effect of BIX on E-cadherin promoter methylation in the AML-193 cell line. 
AML-193 cells were untreated (a) or treated (b) for  72  hours  with  4µM BIX. Percentage 
methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, represents the 
standard deviation of the percentage mean methylation. The sequence analyzed is shown above 
each pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, 
the Y-axis represents the signal intensity (arbitrary units), which is proportional to the number 
of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue, yellow and red colours represent the confidence of the 
sequence pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, 
respectively. 
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 a) Control 
% Methylation : 96.5; SD: 3.3 
 
 
 
 
b) 4 µM BIX 
% Methylation: 96.4; SD: 3.3 
 
Figure 5.23. Effect of BIX on E-cadherin promoter methylation in the Kasumi cell line. 
Kasumi cells were untreated (a) or treated (b) for  72  hours  with  4µM BIX. Percentage 
methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, represents the 
standard deviation of the percentage mean methylation. The sequence analyzed is shown above 
each pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, 
the Y-axis represents the signal intensity (arbitrary units), which is proportional to the number 
of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue, yellow and red colors represent the confidence of the 
sequence pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, 
respectively. 
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5.5. Effect of chaetocin on p15, p21, and E-cadherin expression  
 
5.5.1. Chaetocin-induced re-expression of p15, p21, and E-cadherin  
Histone methylation is an important transcription mark for regulation of gene expression; 
however alterations in histone methylation patterns lead to the permanent silencing of relevant-
cancer genes (Kouzarides, 2007; Sharma et al., 2010). To continue evaluating the effect of 
histone methylation in the silencing of tumor suppressor genes in AML, we analyzed the effect 
of chaetocin, an inhibitor of SUV39H1 histone trimethyltransferase, on p15, p21, and E-
cadherin gene re-expression in AML cell lines. Treatment of AML-193, KG-1a, and Kasumi 
cell lines with 50 to 100 nM chaetocin resulted in a significant increase in p15, p21, and E-
cadherin gene expression (Figure 5.24). p21 expression  increased the most with an ~ 6-fold 
increase and ~ 8-fold increased following treatment with 100 nM chaetocin in AML-193 and 
Kasumi cells, respectively (Figure 5.24c). Chaetocin doses up to 100 nM were required to 
significantly re-express E-cadherin and p15 in AML cell lines (Figure 5.24a and Figure 5.24b). 
 
5.5.2. Chaetocin-mediated expression of p15, p21, and E-cadherin caused changes in 
H3K9 methylation 
To determine if chaetocin induced p15, p21, and E-cadherin gene expression by causing 
changes in promoter H3K9 methylation, we used ChIP assays. Treatment of AML-193 and 
Kasumi cells with 100 nM chaetocin significantly decreased levels of trimethyl-H3K9 at p15 
and E-cadherin promoters to a greater extent than dimethyl-H3K9 (Figure 5.25a and Figure 
5.25b). In contrast to the results observed with DAC, chaetocin decreased H3K9 tri-methylation 
levels at the p21 promoter of AML-193 and Kasumi cell lines (Figure 5.25b). However, 
chaetocin was only able to reduce H3K9 di-methylation levels at the p21 promoter in AML-193 
cells. In Kasumi cells, this treatment increased levels of dimethyl-H3K9, which was similar to 
results found with DAC treatment (Figure 5.25a and Figure 5.17a). We did not observed 
changes in core histone H3 levels, indicating that changes in H3K9 methylation were not due to 
nucleosome depletion (Figure 5.25c). 
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5.5.3. Chaetocin enhanced p15 and E-cadherin expression without promoter 
demethylation 
The ability of chaetocin to enhance expression of hypermethylated silenced genes, 
prompted us to determine whether chaetocin treatment produced changes in the methylation 
status of p15 and E-cadherin promoters. Treatment of AML-193 and Kasumi cell lines with 
chaetocin did not change the methylation state across the analyzed CpG islands in the p15 and 
E-cadherin promoter as indicated by DNA pyrosequencing analysis (Figure 5.26, Figure 27, 
Figure 28 and Figure 29). 
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Figure 5.24. Real time PCR analysis of p15, p21, and E-cadherin expression in AML cell lines. 
AML-193, KG-1a, and Kasumi cell lines were treated with different doses of chaetocin for 72 
hours. P15 (a), E-cadherin (b), and p21 (c) gene expression was analyzed using HPRT as 
endogenous control expression. Error bars represents standard deviation of three independent 
experiments and (*) represents P-value < 0.05 and (**) represent P-value <0.01 between treated 
and untreated cells. Control represents the untreated cells. 
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Figure 5.25. Chromatin immunoprecipitation analysis of the effect of chaetocin on H3K9 di- 
and tri-methylation and H3 associated with the p15, E-cadherin, and p21 promoter in AML cell 
lines. (a) ChIP assay of dimethyl-H3K9 (H3K9Me2) antibodies. (b) ChIP assay of trimethyl- 
H3K9 (H3K9Me3) antibodies. (c) ChIP assay of H3 (H3) antibodies. AML-193 and Kasumi 
cells were treated with Chaetocin (100 nM) or untreated for 72 hours. Histograms show the 
relative fold expression of PCR products (immunoprecipitated DNA) quantified using real time 
PCR. Error bars represent standard deviation of three independent experiments. ** Represents 
P-values < 0.05 and (**) represent P-value <0.01 between treated and untreated cells. Control 
represents the untreated cells. 
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AML-193 p15  
a) Control 
% Methylation: 95.1; SD: 8.0  
 
b) 100 nM Chaetocin 
% Methylation: 95.2; SD: 7.4 
 
 
Figure 5.26. Effect of chaetocin on p15 promoter methylation in AML-193 cell line. AML-193 
cells were untreated (a) or treated (b) for 72 hours with 100 nM chaetocin. Percentage 
methylation is the mean methylation of CpGs in the p15 promoter. SD, represents the standard 
deviation of the percentage mean methylation. The sequence analyzed is shown above each 
pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, the Y-
axis represents the signal intensity (arbitrary units), which is proportional to the number of 
nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Yellow color represents that the sequences pattern matches with a 
confidence between 70-89 percent.  
78 
 
a) Control 
% Methylation: 95.0; SD: 7.4 
 
b) 100 nM Chaetocin% Methylation: 95.7; SD: 5.4 
 
Figure 5.27. Effect of chaetocin on p15 promoter methylation in Kasumi cell line. Kasumi cells 
were untreated (a) or treated (b) for 72 hours with 100 nM chaetocin. Percentage methylation is 
the mean methylation of CpGs in the p15 promoter. SD, represents the standard deviation of the 
percentage mean methylation. The sequence analyzed is shown above each pyrogram, where Y 
represents the location of the cytosine in the CpG. In the pyrogram, the Y-axis represents the 
signal intensity (arbitrary units), which is proportional to the number of nucleotides 
incorporated (as peaks heights) and the X-axis is the dispensation order. The gray bars indicate 
the CpG positions, where the degree of methylation is assessed from the ratio of the peaks 
heights of C and T. Blue color represents that the sequence pattern matches with a confidence 
greater than 90 percent.  
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a) Control 
% Methylation: 95.5; SD: 4.7 
 
b) 100 nM Chaetocin 
% Methylation: 90.6; SD: 10 
 
 
Figure 5.28. Effect of chaetocin on E-cadherin promoter methylation in AML-193 cell line. 
AML-193 cells were untreated (a) or treated (b) for  72  hours  with  4µM BIX. Percentage 
methylation is the mean methylation of CpGs in the E-cadherin promoters. SD, represents the 
standard deviation of the percentage mean methylation. The sequence analyzed is shown above 
each pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, 
the Y-axis represents the signal intensity (arbitrary units), which is proportional to the number 
of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue, yellow and red colors represent the confidence of the 
sequence pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, 
respectively. 
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a) Control 
% Methylation: 90.1; SD: 9.0 
 
 
 
b) 100 nM Chaetocin 
% Methylation: 84.9; SD: 11.1 
 
 
Figure 5.29. Effect of chaetocin on E-cadherin promoter methylation in AML-193 cell line. 
AML-193 cells were untreated (a) or treated (b) for  72  hours  with  4µM BIX. Percentage 
methylation is the mean methylation of CpGs in the E-cadherin promoters. SD, represents the 
standard deviation of the percentage mean methylation. The sequence analyzed is shown above 
each pyrogram, where Y represents the location of the cytosine in the CpG. In the pyrogram, 
the Y-axis represents the signal intensity (arbitrary units), which is proportional to the number 
of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation order. The gray 
bars indicate the CpG positions, where the degree of methylation is assessed from the ratio of 
the peaks heights of C and T. Blue, yellow and red colours represent the confidence of the 
sequence pattern matches: greater than 90 percent, 70-89 percent and less than 70 percent, 
respectively. 
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5.6. The effect of combinatorial treatments of DAC, BIX, and chaetocin on AML cell 
proliferation 
Previous studies in our lab showed that DAC has little effect on AML cell proliferation. 
However, we found that DAC potentiated the anti-proliferative cell response to BIX and 
chaetocin treatment in AML cell lines. Based on this result and the fact that combinations of 
DNMT and HDAC inhibitors work in synergy to induce greater expression of silenced tumor 
suppressor genes in cancer cell lines (Zhu and Otterson, 2003; McGarvey et al., 2006), we 
evaluated the effect of combinatorial treatments of DAC, BIX, and chaetocin on the 
proliferation of AML cells and in the re-activation of tumor suppressor genes in AML cell lines. 
Initially, we determined median effect doses of BIX and chaetocin in the presence and absence 
of DAC on AML-193, KG-1a, and Kasumi cell proliferation using MTT assays. Median doses 
(Dm) were determined based on the MTT assay using CalcuSyn software in accordance with 
equation 1: 
 
Log (Fa/Fu) = m log (D)  m log (Dm)                         (Eq.1) 
 
In equation 1, Fa is the fraction affected for a given dose (D), Fu is the fraction unaffected 
(1-Fa), D is the dose of drug, Dm is the median dose of the drug and m is the slope. The 
fraction affected calculated from MTT data was determined by equation 2: 
 
Fa =           (Proliferation with drug)____        (Eq. 2) 
(Proliferation without drug) 
 
We found that chaetocin induced 50% inhibition of AML cell proliferation at lower doses 
than BIX. However, median-effect doses vary between cell lines due to their sensitivity to 
drugs. Kasumi was the most sensitive cell line in response to BIX, showing a Dm of 828±481 
nM  and  10.33±2.92  nM  for  chaetocin  (Table  5.2 and Figure 5.32). Conversely, KG-1a was 
more  sensitive  to  chaetocin  and  BIX  with  a  Dms  of  7.65±0.36  nM  and  1380±269  nM, 
respectively (Table 5.2 and Figure 5.31). AML-193 was the most resistant cell line to chaetocin 
and BIX with  a Dms  of  2590±163  nM  and  17±1.74  nM,  respectively  (Table  5.2  and  Figure 
5.30).  
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In all AML cell lines tested, median doses were reduced for chaetocin and BIX in the 
presence of DAC, confirming that DAC potentiates the effect of these drugs on the proliferation 
of AML cells (Table 5.2). Chaetocin Dms were reduced in the order of 3 to 5 times in all AML 
cell lines studied (Table 5.2). In AML-193, the Dm for BIX was as well reduced 3 times. 
However, in Kasumi and KG-1a the Dm for BIX was slightly reduced (Table 5.2). The ability 
of DAC to potentiate the activity of BIX and chaetocin may be explained by the correlation 
between decreased DNA and histone methylation and gene re-activation. This hypothesis can 
be supported by previous studies carried out in the Geyer lab, where re-activation of 
hypermethylated tumor suppressor gene RIZ1 takes place when AML cells are treated with 
chaetocin and DAC (Geyer, unpublished).  
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Table 5.2. Median doses of chaetocin and BIX in AML cell lines 
Cell line 
 
+/- DAC Drugs Median dose  (nM)* 
AML-193 - BIX 2590 ± 163 
AML-193 + BIX 770 ± 290 
AML-193 - Chaetocin 17 ± 1.74 
AML-193 + Chaetocin 3.30 ± 1.56 
KG-1a  - BIX 1380 ± 269 
KG-1a + BIX 1160 ± 307 
KG-1a - Chaetocin 7.65 ± 0.36 
KG-1a + Chaetocin 2.53 ± 0.53 
Kasumi - BIX 828 ± 481 
Kasumi + BIX 793 ± 189 
Kasumi - Chaetocin 10.33 ± 2.92 
Kasumi + Chaetocin 1.96 ± 0.43 
Cells were treated for 72 hours with BIX and chaetocin in combination in presence and absence 
of DAC (+/-). * Errors represents 95% confidential interval. 
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Figure 5.30. Median effect plots of BIX and chaetocin in AML-193 cell line. AML-193 cells 
were treated for 72 hours with BIX (a) or chaetocin (b). Fa indicates fraction affected for each 
drug, Fu indicates fraction unaffected (vehicle control), and D represents doses for each drug. 
DMSO was used as a vehicle control for both drugs. The median doses (Dm) are found from 
the graphs by taking the antilog of the X intercept.  
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Figure 5.31. Median effect plots of BIX and chaetocin in KG-1a cell line. KG-1a cells were 
treated for 72 hours with BIX (a) or chaetocin (b). Fa indicates fraction affected for each drug, 
Fu indicates fraction unaffected (vehicle control), and D represents doses for each drug. DMSO 
was used as a vehicle control for both drugs. The median doses (Dm) are found from the graphs 
by taking the antilog of the X intercept. 
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Figure 5.32. Median effect plots of BIX and chaetocin in Kasumi cell line. Kasumi cells were 
treated for 72 hours with BIX (a) or chaetocin (b). Fa indicates fraction affected for each drug, 
Fu indicates fraction unaffected (vehicle control), and D represents doses for each drug. DMSO 
was used as a vehicle control for both drugs. The median doses (Dm) are found from the graphs 
by taking the antilog of the X intercept. 
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Based on the ability of DAC to potentiate anti-proliferative response of chaetocin and BIX 
in AML cell lines, we assessed the synergism or antagonism effects of BIX and chaetocin in 
presence and absence of DAC. Interaction between drugs was tested using the median effect 
plot analysis method developed by Chou and Talaly (1977). This method evaluates the nature of 
interaction of two drugs using the combination index (CI) value, which provides the qualitative 
information of drug interaction nature and is represented by equation 3: 
CI= (D
A,X
/ D
X,A
) + (D
B,X
/ D
X,B
)                      (Eq. 3) 
In equation 3, D
A,X 
 and D
B,X
 are  concentrations of drugs A and B used in combination to 
achieve X% drug effect. D
X,A
 and D
X,B
 are the concentrations of each drug (A and B) that alone 
cause that X% effect. CI is the combination index value. Combination index values can be 
represented by CI and isobologram plots. Isobolograms are defined as a measure of 
effectiveness of drug interaction, where two drugs, A and B, are required to produce a defined 
single agent effect (e,g., IC
50
/Dm). D
A
 and D
B
 used as single agents are placed on the x and y 
axes in a two-coordinate plot. The line connecting these points (drug A,
 
D
A
, and drug B, D
B
, at 
an effect above the line indicates that drug A and B at x and y doses synergistically act to cause 
an effect greater than that caused by the drugs alone. Conversely, when a combination results in 
a reduced effect (le
x
x
indicating a CI value more than 1, showing antagonism. Synergism will be described as the 
opposite of antagonism, where CI value is less than 1.  In summary, if the CI is equal to 1, the 
drug combination is additive, CI is greater than 1, then drugs display antagonism, and if the CI 
is less than 1, drugs display synergism (Zhao et al., 2004; Tallarida, 2006; Chou, 2006). 
Drug combination studies were used to measure drug interactions and potentiation of anti-
proliferative response in AML cell lines. CI values were calculated at different effect levels, 
denoted ED
X
 (x= 50, 75, and 90) using CalcuSyn software (Table 5.3). In AML-193, BIX and 
chaetocin treatment displayed antagonistic activity under the drug doses used in study (Figure 
5.33). The mean combination index values +/- SD in AML-193 cell lines for different effect 
levels were ED
50
: 1.49 +/- 0.38, ED
75
: 1.48 +/- 0.32, and ED
90
: 1.48 +/- 0.28 (Table 5.3).  In the 
presence of DAC, antagonism became significant, but it was slightly reduced as the effect-
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levels increased. CI values for ED
50
, ED
75
, and ED
90
 were 2.73 +/- 0.66, 2.18 +/- 0.42, and 1.74 
+/- 0.28, respectively (Table 5.3, Figure 5.33a and Figure 5.33c). 
In the case of KG-1a and Kasumi cell lines, a synergistic anti-proliferative effect between 
BIX and chaetocin was observed in the absence of DAC. In KG-1a, mean CI values +/- SD for 
effect levels were ED
50
: 0.77 +/- 0.12, ED
75
: 0.70 +/- 0.09, and ED
90
: 0.64 +/- 0.08 (Table 5.3 
and Figure 5.34). In Kasumi cells, CI values were ED
50
: 0.94 +/- 0.23, ED
75
: 0.93 +/- 0.18, and 
ED
90
: 0.92 +/- 0.22 (Table 5.3 and Figure 5.35). In the presence of DAC, BIX, and chaetocin 
treatment presented an antagonistic interaction at the 50% effect level in KG-1a (ED
50
: 
1.34±0.42) and Kasumi (ED
50
: 1.52±0.66) cell lines (Table 5.3, Figure 5.34 and Figure 5.35). 
However, as the effect level increased at 90% BIX and chaetocin treatment displayed 
synergistic activity in KG-1a (ED
90
: 0.86±0.21) and Kasumi (ED
90
: 0.58±0.20) cells (Table 5.3, 
Figure 5.34 and Figure 5.35).    
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Table 5.3. CI values for combination of BIX with chaetocin in AML cell lines. 
  CI values at inhibition of 
Cell line +/- DAC 50% 75% 90% 
AML-193 - 1.49±0.38 1.48±0.32 1.48±0.28 
AML-193 + 2.73±0.66 2.18±0.42 1.74±0.28 
KG-1a  - 0.77±0.12 0.70±0.09 0.64±0.08 
KG-1a + 1.34±0.42 1.08±0.28 0.86±0.21 
Kasumi - 0.94±0.23 0.93±0.18 0.92±0.22 
Kasumi + 1.52±0.66 0.92±0.36 0.58±0.20 
Cells were treated for 72 with BIX and chaetocin in combination in presence of absence of 
DAC (+/-). CI values = 1 indicates additive effect, <1synergism, >1 antagonism. 
*Data represents ± the mean S.D. 
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Figure 5.33. Drug combination effect of BIX and chaetocin in the AML-193 cell line. (a) CI 
plots of BIX and chaetocin in presence or absence of DAC. Isobolograms for different effect 
doses (ED50, ED75, and ED 90) of BIX and chaetocin in the absence  or the presence  of DAC 
are shown in figure (b) and (c), respectively. AML-193 cells were co-treated for 72 hours with 
BIX  and  chaetocin  in  presence  and  absence  of  1  µM  DAC.  Effect  of  combinations  were 
assessed by MTT assays and estimated using the CalcuSyn software after cells were incubated 
with co-treatment of BIX and chaetocin + and  DAC. In CI plots, the horizontal line has a 
value equal to 1 and represents the line of additivity. CI < 1 indicates synergy, CI= 1 additive 
effect, and CI >1 indicates antagonism. In isobolograms, the diagonal line is the line of 
additivity. Experimental data points, represented by symbols show the different effect levels. 
Symbols located below, on, or above the line indicate synergy, additive or antagonism, 
respectively.    
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Figure 5.34. Drug combination effect of BIX and chaetocin in the KG-1a cell line. (a) CI plots 
of BIX and chaetocin in presence or absence of DAC. Isobolograms for different effect doses 
(ED50, ED75, and ED 90) of BIX and chaetocin in the absence or the presence of DAC are 
shown in figure (b) and (c), respectively. KG-1a cells were co-treated for 72 hours with BIX 
and chaetocin in presence and absence of 1 µM DAC. Effect of combinations were assessed by 
MTT assays and estimated using the CalcuSyn software after cells were incubated with co-
treatment of BIX and chaetocin + and  DAC. In CI plots, the horizontal line has a value equal 
to 1 and represents the line of additivity. CI < 1 indicates synergy, CI= 1 additive effect, and CI 
>1 indicates antagonism. In isobolograms, the diagonal line is the line of additivity. 
Experimental data points, represented by symbols show the different effect levels. Symbols 
located below, on, or above the line indicate synergy, additive or antagonism, respectively.  
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Figure 5.35. Drug combination effect of BIX and chaetocin in the Kasumi cell line. (a) CI plots 
of BIX and chaetocin in presence or absence of DAC. Isobolograms for different effect doses 
(ED50, ED75, and ED 90) of BIX and chaetocin in the absence or the presence of DAC are 
shown in figure (b) and (c), respectively. Kasumi cells were co-treated for 72 hours with BIX 
and chaetocin in presence and absence of 1 µM DAC. Effect of combinations were assessed by 
MTT assays and estimated using the CalcuSyn software after cells were incubated with co-
treatment of BIX and chaetocin + and  DAC. In CI plots, the horizontal line has a value equal 
to 1 and represents the line of additivity. CI < 1 indicates synergy, CI= 1 additive effect, and CI 
>1 indicates antagonism. In isobolograms, the diagonal line is the line of additivity. 
Experimental data points, represented by symbols show the different effect levels. Symbols 
located below, on, or above the line indicate synergy, additive or antagonism, respectively. 
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5.7. Combinatorial treatments of DAC, BIX, and chaetocin influenced gene activation in 
AML cells 
While silencing of p15, p21, and E-cadherin genes occurs in AML, little is known about the 
repressor components that effect epigenetic silencing of these genes. Previously, we found that 
p15 and E-cadherin gene promoters were hypermethylated in AML cell lines, while the p21 
promoter was completely unmethylated. Moreover, it was found that treatment with DAC and 
chaetocin as single agents induced expression of the hypermethylated genes p15 and E-cadherin 
and also the non-hypermethylated p21 gene. To study the relationship between epigenetic 
events that lead to reactivation of epigenetically silenced genes, we established combinations of 
DAC, BIX, and chaetocin that lead to re-activation of p15, p21, and E-cadherin genes in the 
AML cell lines studied. For these assays, we chose concentrations of DAC, BIX, and chaetocin, 
where AML cell lines showed an enhancement of p15, p21, and E-cadherin expression. We 
used  1  µM DAC  for  experiments  that  involved  p15  and  p21  genes  and  8  µM DAC  for  E-
cadherin gene in AML-193. In KG-1a and Kasumi cell lines 4 µM DAC were used for all three 
genes.  Four micromolar  (4  µM) BIX  and  100  nM  chaetocin were  used  for  p15,  p21  and  E-
cadherin genes in all AML cell lines tested. 
 
5.7.1. Chaetocin and DAC in combination reactivated expression of p15 and E-cadherin 
genes by reducing levels of promoter methylation and H3K9 tri-methylation 
Co-treatment of AML cell lines with DAC and chaetocin induced re-expression of p15 and 
E-cadherin genes with a greater effect than treatment with DAC or chaetocin alone (Figure 
5.36a and Figure 5.36b). Moreover, this enhanced p15 and E-cadherin expression in AML-193 
and Kasumi cell lines was accompanied by promoter demethylation and a reduction of H3K9 
tri-methylation levels as analyzed by DNA pyrosequencing and ChIP assays, respectively 
(Figure 5.36a, Figure 5.36b, Figure 5.37, Figure 5.38, Figure 5.39, Figure 5.40, Figure 5.41a 
and Figure 5.41b). No changes were observed in histone H3 levels, indicating that changes in 
H3K9 methylation were not due to nucleosome depletion (Figure 5.41c). 
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Figure 5.36. Real time PCR analysis of p15, p21, and E-cadherin expression upon treatment 
with chaetocin and DAC in combination in AML cell lines. AML-193, KG-1a, and Kasumi cell 
lines were treated with chaetocin (100 nM) and following concentrations of DAC: AML-193: 
p15  and  p21  (1  µM),  E-cadherin  (8  µM);  Kasumi:  p15,  E-cadherin,  and  p21  (4  µM). 
Histograms show the relative fold expression of p15 (a), E-cadherin (b), and p21 (c) gene 
expression in AML-193, KG-1a, and Kasumi cell lines. HPRT was used as endogenous control 
expression. Error bars represents standard deviation of three independent experiments and (*) 
represents P-value < 0.05 and (**) represent P-value <0.01 between treated and untreated cells. 
Control, represents the untreated cells.  
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a) Control 
% Methylation: 95.1; SD: 8.0  
b) 1 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
c) 100 nM Chaetocin + 1 µM DAC 
% Methylation: 67; SD: 12 
 
Figure 5.37.  Effects of chaetocin and DAC combinatorial treatment on p15 promoter 
methylation in AML-193 cell line. AML-193 cells were co-treated for 72 hours with 100 nM 
chaetocin and 1 µM DAC. Percentage methylation is the mean methylation of CpGs in the p15 
promoter. SD, represents the standard deviation of the percentage mean methylation. The 
sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue and yellow colors 
represent the confidence of the sequence pattern matches: greater than 90 percent and between 
70-89 percent, respectively. 
96 
 
 a)  Control 
% Methylation: 95%; SD: 4.9 
 
b) 4 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
c) 100 nM chaetocin + 4 µM DAC 
% Methylation: 68%; SD: 12.1 
 
Figure 5.38. Effects of chaetocin and DAC in combinatorial treatment on p15 promoter 
methylation in Kasumi cell line. Kasumi cells were co-treated for 72 hours with 100 nM 
chaetocin and 1 µM DAC. Percentage methylation is the mean methylation of CpGs in the p15 
promoter. SD, represents the standard deviation of the percentage mean methylation. The 
sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue and yellow colors 
represent the confidence of the sequence pattern matches: greater than 90 percent and between 
70-89 percent, respectively. 
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a) Control  
% Methylation: 95.5; SD:4.7 
 
b) 8 µM DAC 
% Methylation: 66.8; SD: 7.0 
 
b) 100 nM chaetocin + 8 µM DAC 
% Methylation: 88; SD: 4.2 
 
Figure 5.39. Effects of chaetocin and DAC in combinatorial treatment on E-cadherin promoter 
methylation in AML-193 cell line. AML-193 cells were co-treated for 72 hours with 100 nM 
chaetocin and 8 µM DAC. Percentage methylation is the mean methylation of CpGs in the E-
cadherin promoter. SD, represents the standard deviation of the percentage mean methylation. 
The sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue, yellow and red 
colors represent the confidence of the sequence pattern matches: greater than 90 percent, 70-89 
percent and less than 70 percent, respectively. 
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 a) Control 
% Methylation: 90.1; SD: 9.0 
 
b) 4 µM DAC 
% Methylation: 55.8; SD: 9.2  
 
c) 100 nM chaetocin + 4 µM DAC 
% Methylation: 59; SD: 5.3  
 
Figure 5.40. Effect of chaetocin and DAC combinatorial treatment on E-cadherin promoter 
methylation in Kasumi cell line. Kasumi cells were co-treated for 72 hours with 100 nM 
chaetocin and 4 µM DAC. Percentage methylation is the mean methylation of CpGs in the E-
cadherin promoter. SD, represents the standard deviation of the percentage mean methylation. 
The sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue, yellow and red 
colors represent the confidence of the sequence pattern matches: greater than 90 percent, 70-89 
percent and less than 70 percent, respectively. 
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5.7.2. Chaetocin and DAC in combination reactivated expression of p21 gene by causing 
changes on H3K9 di-methylation 
p21 gene was not silenced by promoter hypermethylation in AML cell lines; however treatment 
of DAC led to re-expression of p21 and caused changes in H3K9 promoter methylation levels. 
To determine whether the combination of chaetocin and DAC potentiates re-expression of p21 
gene by causing changes in H3K9 methylation levels, we used real time PCR to measure the 
expression level of p21 and ChIP assays to determine changes in promoter H3K9 methylation 
in the AML cell lines studied. Co-treatment of AML-193, KG-1a, and Kasumi cell lines with 
DAC and chaetocin caused a higher level of p21 expression than observed with treatments with 
either DAC or chaetocin alone (Figure 5.36c). In contrast to the results observed with DAC and 
chaetocin treatments alone, the combination of DAC and chaetocin significantly reduced H3K9 
di-methylation levels at p21 promoter as analyzed by ChIP assays (Figure 5.41c). However, this 
treatment did not reduce trimethyl H3K9 levels as was observed with chaetocin treatment alone. 
In contrast, H3K9 tri-methylation at p21 promoter was increased in AML-193 and Kasumi cell 
lines in response to DAC and chaetocin co-treatment (Figure 5.41c). 
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Figure 5.41. Chromatin immunoprecipitation analysis of the effect of DAC and chaetocin in 
combination on H3K9 di- and tri-methylation and H3 associated with the p15, E-cadherin and 
p21 promoter in AML cell lines. AML-193 and Kasumi cells were treated for 72 hours with 
chaetocin (100 nM) and DAC as followed: AML-193: p15 and p21 (1 µM), E-cadherin (8 µM); 
Kasumi: p15, E-cadherin and p21 (4 µM). Cross-linked protein/DNA was immunoprecipitated 
with dimethyl-H3K9 (H3K9Me2) antibody or trimethyl-H3K9 (H3K9Me3) antibody or of H3 
(H3). Histograms show the relative fold expression of PCR products (immunoprecipitated 
DNA) of p15 (a), E-cadherin (b), and p21 (c) genes quantified using real time PCR. Error bars 
represent standard deviation. ** Represents P-values < 0.05 and (**) represent P-value < 0.01 
between treated and untreated cells. Control, represents the untreated cells.  
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5.7.3. Co-treatment of BIX and DAC caused differential expression of p15, p21 and E-
cadherin genes in AML cell lines 
We showed that DAC potentiated the effect of BIX on AML cells proliferation, induced 
p15, p21 and E-cadherin expression, and caused changes in promoter DNA methylation and 
histone H3K9 methylation in AML cell lines. To study the relationship between DNA 
methylation and histone H3K9 di-methylation at the p15, p21, and E-cadherin promoters, we 
measured the effect of combinations of DAC and BIX on gene expression, DNA methylation, 
and H3K9 methylation in AML cell lines. Co-treatment of AML-193, KG-1a, and Kasumi cells 
with BIX and DAC was able to induce p21 expression (Figure 5.42c). However, significant 
expression in p15 and E-cadherin genes were only evident in KG-1a and Kasumi cells, but not 
in AML-193 cells where this treatment did not cause p15 and E-cadherin re-expression (Figure 
5.42a and Figure 5.42b). Treatment with BIX and DAC in combination induced p15, p21, and 
E-cadherin expression to a greater extent than that of each drug alone. Surprisingly, this 
treatment had little effect on reversing p15 and E-cadherin promoter methylation than treatment 
with DAC alone (Figure 5.43, Figure 5.44, Figure 5.45 and Figure 5.46).  
We also observed significant changes in H3K9 di- and tri-methylation levels at p15 and E-
cadherin promoters following BIX and DAC co-treatment as analyzed by ChIP assays (Figure 
5.47a and Figure 5.47b). However, we only observed that at p21 promoter, combination of BIX 
and DAC preferentially caused reduction of H3K9 di-methylation in Kasumi cells, but not as 
much as that caused by treatment of BIX alone (Figure 5.47c). We did not observed changes in 
histone H3 levels in any of the analyzed genes, indicating that changes in H3K9 methylation 
were not due to nucleosome depletion (Figure 5.47). 
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Figure 5.42. Real time PCR analysis of p15, p21 and E-cadherin expression upon treatment 
with BIX and DAC in combination in AML cell lines. AML-193, KG-1a, and Kasumi cell lines 
were treated with BIX (4 µM) and following concentrations of DAC: AMl-193: p15 and p21 (1 
µM),  E-cadherin  (8  µM);  Kasumi:  p15,  E-cadherin  and  p21  (4  µM).  Histograms  show the 
relative fold expression of p15 (a), E-cadherin (b) and p21(c) gene expression in AML-193, 
KG-1a and Kasumi cell lines. HPRT was used as endogenous control expression. Error bars 
represents standard deviation of three independent experiments and (*) represents P-value < 
0.05 and (**) represent P-value <0.01 between treated and untreated cells. Control, represents 
the untreated cells. 
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a) Control 
% Methylation: 95.1; SD: 8.0  
b) 1 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
c) 4 µM BIX + 1 µM DAC 
% Methylation: 67; SD: 12 
 
Figure 5.43. Effects of BIX and DAC combinatorial treatment on p15 promoter methylation in 
AML-193 cell line. AML-193 cells were co-treated for 72 hours with 4 µM BIX and 1 µM 
DAC. Percentage methylation is the mean methylation of CpGs in the E-cadherin promoter. 
SD, represents the standard deviation of the percentage mean methylation. The sequence 
analyzed is shown above each pyrogram, where Y represents the location of the cytosine in the 
CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is 
proportional to the number of nucleotides incorporated (as peaks heights) and the X-axis is the 
dispensation order. The gray bars indicate the CpG positions, where the degree of methylation 
is assessed from the ratio of the peaks heights of C and T. Blue, yellow and red colors represent 
the confidence of the sequence pattern matches: greater than 90 percent, 70-89 percent and less 
than 70 percent, respectively. 
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a) Control 
% Methylation: 95%; SD: 4.9 
 
b) 4 µM DAC 
% Methylation: 57.7%; SD: 6.2 
 
c) 4 µM BIX + 4 µM DAC 
% Methylation: 63%; SD: 11.7 
 
Figure 5.44. Effect of BIX and DAC combinatorial treatment on p15 promoter methylation in 
Kasumi cell line. Kasumi cells were co-treated for 72 hours with 4 µM BIX and 4 µM DAC. 
Percentage methylation is the mean methylation of CpGs in the E-cadherin promoter. SD, 
represents the standard deviation of the percentage mean methylation. The sequence analyzed is 
shown above each pyrogram, where Y represents the location of the cytosine in the CpG. In the 
pyrogram, the Y-axis represents the signal intensity (arbitrary units), which is proportional to 
the number of nucleotides incorporated (as peaks heights) and the X-axis is the dispensation 
order. The gray bars indicate the CpG positions, where the degree of methylation is assessed 
from the ratio of the peaks heights of C and T. Blue color represents that the sequence pattern 
matches with a confidence greater than 90 percent. 
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a) Control  
% Methylation: 95.5; SD:4.7 
 
b) 8 µM DAC 
% Methylation: 66.8; SD: 7.0 
 
b) 4 µM BIX + 8 µM DAC 
% Methylation: 84%; SD: 5.1 
Figure 5.45. Effect of BIX and DAC combinatorial treatment on E-cadherin promoter 
methylation in AML-193 cell line. AML-193 cells were co-treated for 72 hours with 4 µM BIX 
and 8 µM DAC. Percentage methylation  is  the mean methylation  of CpGs  in  the E-cadherin 
promoter. SD, represents the standard deviation of the percentage mean methylation. The 
sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue, yellow and red 
colors represent the confidence of the sequence pattern matches: greater than 90 percent, 70-89 
percent and less than 70 percent, respectively. 
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a) Control 
% Methylation: 90.1; SD: 9.0 
 
b) 4 µM DAC 
% Methylation: 55.8; SD: 9.2  
 
b) 4 µM BIX + 4 µM DAC 
% Methylation: 80; SD: 4.8  
 
Figure 5.46. Effect of BIX and DAC combinatorial treatment on E-cadherin promoter 
methylation in Kasumi cell line. Kasumi cells were co-treated for 72 hours with 4 µM BIX and 
4 µM  DAC.  Percentage  methylation  is  the  mean  methylation  of  CpGs  in  the  E-cadherin 
promoter. SD, represents the standard deviation of the percentage mean methylation. The 
sequence analyzed is shown above each pyrogram, where Y represents the location of the 
cytosine in the CpG. In the pyrogram, the Y-axis represents the signal intensity (arbitrary units), 
which is proportional to the number of nucleotides incorporated (as peaks heights) and the X-
axis is the dispensation order. The gray bars indicate the CpG positions, where the degree of 
methylation is assessed from the ratio of the peaks heights of C and T. Blue and red colors 
represent the confidence of the sequence pattern matches: greater than 90 percent and less than 
70 percent, respectively. 
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Figure 5.47. Chromatin immunoprecipitation analysis of the effect of DAC and BIX in 
combination on H3K9 di- and tri-methylation and H3 associated with the p15, E-cadherin, and 
p21 promoters in AML cell lines. AML-193 and Kasumi cells were treated for 72 hours with 
BIX  (4  µM)  and  DAC  as  followed:  AML-193:  p15  and  p21  (1  µM),  E-cadherin  (8  µM); 
Kasumi: p15, E-cadherin and p21 (4 µM). Cross-linked protein/DNA was immunoprecipitated 
with dimethyl-H3K9 (H3K9Me2) antibody or trimethyl-H3K9 (H3K9Me3) antibody or of H3 
(H3). Histograms show the relative fold expression of PCR products (immunoprecipitated 
DNA) of p15 (a), E-cadherin (b), and p21 (c) genes quantified using real time PCR. Error bars 
represent standard deviation of three independent experiments. ** Represents P-values < 0.05 
and (**) represent P-value <0.01 between treated and untreated cells. Control, represents the 
untreated cells.  
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5.7.4. The combination of BIX and chaetocin induced differential p15 and E-cadherin 
expression and increased H3K9 tri-methylation levels 
To evaluate whether coordinated changes in promoter H3K9 di- and tri-methylation 
influence re-expression of silenced tumor suppressor genes in AML, we measured the effect of 
the combination of BIX and chaetocin on p15 and E-cadherin gene expression and promoter 
H3K9 methylation using real time PCR and ChIP assays, respectively. Combinatorial treatment 
of BIX and chaetocin in KG-1a and Kasumi cells enhanced p15 and E-cadherin expression 
similar to those levels observed with combinations of DAC with BIX and DAC with chaetocin, 
and to a greater extent than p15 and E-cadherin expression caused by single drug treatments 
(Figure 5.48a and Figure 5.48b). These results suggested that p15 and E-cadherin genes in 
Kasumi and KG-1a cells required changes on DNA methylation and H3K9 di- and tri-
methylation in order to be re-activated in AML cell lines. In contrast, we found that co-
treatment of AML-193 cells with BIX and chaetocin did not induce p15 and E-cadherin 
expression (Figure 5.48a and Figure 5.48b). These correlated with results observed in drug 
combination studies, where co-treatment of BIX and chaetocin displayed an antagonistic 
activity in AML-193 cell proliferation indicating that combination of these epigenetic inhibitors 
results in a negative interaction that interfere with drug activity.  
In order to determine whether p15 and E-cadherin re-expression can be achieved by 
combining changes on H3K9 di- and tri-methylation, ChIP assays were performed. Co-
treatment of Kasumi cells with BIX and chaetocin did not reduce H3K9 methylation levels at 
p15 and E-cadherin promoters (Figure 5.49a and Figure 5.49b). Surprisingly, we observed that 
treatment of AML-193 with combination of BIX and chaetocin significantly increased 
trimethyl-H3K9 levels at p15 and E-cadherin promoters (Figure 5.49a and Figure 5.49b); which 
supports our previous results that showed that this combination did not cause re-expression of 
p15 and E-cadherin genes (Figure 5.49a and Figure 5.49b). 
 
5.7.5. BIX and chaetocin in combination induced expression of p21 gene and increased 
promoter H3K9 di- and tri-methylation  
We measured the effect of combining BIX and chaetocin in the re-activation of p21 gene in 
AML cell lines. p21 expression following co-treatment with BIX and chaetocin was 
significantly induced to levels greater than that observed with either drug alone (Figure 5.31c).  
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Using ChIP assays, we showed that co-treatment of AML cell lines with BIX and chaetocin 
did not reduce H3K9 di- and tri-methyl levels at p21 promoter, but instead levels of di- and tri-
methyl H3K9 significantly increased (Figure 5.49c). These results suggested that H3K9 
methylation itself might be a positive regulatory event in the expression of p21 gene or changes 
in H3K9 methylation leads to interaction with other epigenetic events for regulation of p21 
gene. No changes were observed in histone H3 levels in any of the analyzed genes, indicating 
that changes in H3K9 methylation were not due to nucleosome depletion (Figure 5.49).  
In summary, a decrease in DNA methylation and H3K9 tri-methylation seems to be the 
major epigenetic events by which hypermethylated genes, such as p15 and E-cadherin can be 
re-expressed in AML cell lines. In contrast, for p21 gene, which contains a non-
hypermethylated promoter, regulation of H3K9 di- and tri-methylation levels appears to be a 
main event for its activation.  
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Figure 5.48. Real time PCR analysis of p15, p21, and E-cadherin expression upon treatment 
with chaetocin and BIX in combination in AML cell lines. AML-193, KG-1a and Kasumi cell 
lines were co-treated with chaetocin (100 nM) and BIX (4 µM) for 72 hours. Histograms show 
the relative fold expression of P15 (a), E-cadherin (b), and p21(c) gene expression in AML-193, 
KG-1a, and Kasumi cell lines. HPRT was used as endogenous control expression. Error bars 
represents standard deviation of three independent experiments and (*) represents P-value < 
0.05 and (**) represent P-value <0.01 between treated and untreated cells. Control, represents 
the untreated cells. 
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Figure 5.49. Chromatin immunoprecipitation analysis of the effect of chaetocin and BIX in 
combination on H3K9 di- and tri-methylation and H3 associated with the p15, E-cadherin and 
p21 promoter in AML cell lines. AML-193 and Kasumi cells were co-treated with BIX (4 µM) 
and chaetocin (100 nM) for 72 hours. Cross-linked protein/DNA was immunoprecipitated with 
dimethyl-H3K9 (H3K9Me2) antibody or trimethyl-H3K9 (H3K9Me3) antibody or of H3 (H3). 
Histograms show the relative fold expression of PCR products (immunoprecipitated DNA) of 
p15 (a), E-cadherin (b), and p21 (c) genes quantified using real time PCR. Error bars represent 
standard deviation of three independent experiments. ** Represents P-values < 0.05 and (**) 
represent P-value <0.01 between treated and untreated cells. Control, represents the untreated 
cells. 
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6. DISCUSSION 
 
Epigenetic silencing of tumor suppressor genes involved in cell cycle control and 
suppression of metastasis, such as p15, p21, and E-cadherin, are associated with AML 
development (Corn et al., 2000; Melki et al., 1999, 2000; Boultwood, 2007). Emerging interest 
in using epigenetic inhibitors that reverse the aberrant silencing of tumor suppressor genes in 
cancer, prompted us to evaluate strategies to re-express p15, p21, and E-cadherin genes in AML 
cell lines. Table 6.1, Table 6.2 and Table 6.3, show a summary of the epigenetic regulatory 
events that occur at p15, E-cadherin and p21 genes upon treatment with epigenetic drugs.  
 
 
Table 6.1. Epigenetic regulation of p15 gene upon treatment with epigenetic inhibitors, DAC, 
BIX and chaetocin 
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Table 6.2. Epigenetic regulation of E-cadherin gene upon treatment with epigenetic inhibitors, 
DAC, BIX and chaetocin 
 
 
 
Table 6.3. Epigenetic regulation of p21gene upon treatment with epigenetic inhibitors, DAC, 
BIX and chaetocin  
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6.1. Epigenetic regulation of p15, p21, and E-cadherin genes upon treatment with DAC, 
BIX and chaetocin  
In this study, the observed silencing of p15 and E-cadherin genes in AML-193 and Kasumi 
cell lines correlated with increased promoter hypermethylation. p21 was also silenced in the 
AML cell lines tested, but in contrast to p15 and E-cadherin, we did not observe 
hypermethylation at p21 promoter. Instead, we found that the CpGs analyzed at the p21 
promoter were completed unmethylated. This observation suggests that methylation 
independent epigenetic mechanisms contribute to p21 silencing in AML-193 and Kasumi cell 
lines.  
To efficiently evaluate re-activation of p15, p21, and E-cadherin genes in AML cell lines 
using the epigenetic inhibitors, DAC, BIX-01294, and chaetocin, we first determined the effect 
of these drugs on AML cell proliferation and optimized concentration of drugs that caused an 
enhancement of gene expression. Treatment with BIX and chaetocin inhibited viability and 
proliferation of AML-193, KG-1a, and Kasumi cell lines, whereas DAC had no effect on cell 
viability and proliferation as previously reported (Geyer et al., unpublished). DAC however, 
potentiated the anti-proliferative activity of BIX and chaetocin in AML cell lines. Loss of cell 
proliferation was correlated with changes in cell cycle profile, where a decrease in cell 
population in the S dividing phase and arrest in G1 and subG1 was observed following 
treatment with BIX and chaetocin.  
In AML cell lines, treatment with DAC enhanced p15 and E-cadherin expression and 
decreased promoter and H3K9 methylation. Interestingly, we found that DAC treatment also 
caused re-expression of the unmethylated p21 gene, but instead of decreasing promoter H3K9 
methylation, it increased H3K9 di-methylation levels at p21 promoter of AML-193 and Kasumi 
cell lines and H3K9 tri-methylation at the p21 promoter of AML-193 cells. The ability of DAC 
to enhance expression and induce chromatin remodelling of unmethylated genes (Nguyen et al., 
2002; Coombes et al., 2003; Wu et al., 2005; Scott et al., 2006) suggested that it may have 
effect on other epigenetic changes that are independent of DNA demethylation. Importantly, the 
finding that enhanced p21 expression was accompanied with an increase in H3K9 di- and tri-
methylation was in disagreement with the well recognized H3K9 tri-methylation gene-silencing 
mark and its association to heterochromatin regions (Heard et al., 2001; Peters et al., 2003; Rice 
et al., 2003). Our findings concur with previous studies where Vakoc and colleagues (2005) 
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presented a surprising finding that trimethyl-H3K9 mark is present in transcribed regions of 
genes (Vakoc, et al., 2005). More importantly, Wiencke (2008) recently showed that 
unmethylated genes that have been expressed in acute leukemic cell lines present in their 
promoter increased levels of H3K9 di and tri-methylation as well as H3K9 acetylation marks 
(Wiencke et al., 2008). A possible explanation for this observation is that H3K9 di- and tri-
methylation are dynamic intermediates of different methylated states that regulate different 
functional chromatin rearrangements and therefore effect expression of genes in a specific-gene 
manner. 
While H3K9 di-methylation levels mostly decreased at the p15, p21 and E-cadherin gene-
promoters upon treatment with BIX, major changes on gene expression were not observed, 
except in AML-193 and Kasumi cell lines where E-cadherin and p21 genes were expressed 
upon treatment with highest doses of chaetocin, respectively. Thus, it appears that H3K9 di-
methylation per se is not a dominant event in transcriptional silencing of p15, p21, and E-
cadherin genes in AML. Further, we showed that chaetocin treatment significantly enhanced 
p15 expression and decreased H3K9 methylation levels at p15 and E-cadherin promoter without 
inducing promoter demethylation. Interestingly, these results demonstrated that H3K9 
demethylation was a dominant event over promoter demethylation in re-expressing genes 
silenced by promoter hypermethylation in AML. Moreover, these results agree with previous 
observations found in the Geyer lab, which demonstrated that blocking the activity of the 
SUV39H1 enzyme with shRNA lead to the re-expression of the hypermethylated genes, p15 
and E-cadherin, without effecting promoter methylation (Lakshmikuttyamma, et al., 2010). 
Similar observations of gene reactivation in the absence of promoter demethylation have been 
reported in studies that involved decreasing the H3K27 methyltransferase, EZH2 and H3K9 
deacetylase, SIRT1 activities (McGarvey et al., 2007; Cao et al., 2008; Kondo et al., 2008). In 
addition, we also observed that chaetocin re-expressed p21 gene in AML-193 cell line, but in 
contrast to those results found with DAC, promoter H3K9 tri-methylation levels were reduced 
upon chaetocin treatment. Thus, due to the controversy between this result and the results 
observed with DAC treatment, we cannot conclude whether H3K9-trimethylation is a positive 
transcriptional mark in the active p21 gene-promoter. However, we could hypothesize that up- 
or down-regulation of H3K9-trimethylation levels at the p21 promoter might be associated as a 
secondary step activated by another dominant epigenetic event.  
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6.2. Epigenetic regulation of p15, p21, and E-cadherin genes upon treatment with 
combinations of epigenetic inhibitors  
A large body of evidence has shown that epigenetic interaction between DNA methylation 
and histone modifications leads to transcriptional gene silencing. Several studies have 
established that SUV39H1-mediated H3K9 methylation may initiate promoter methylation by 
providing a binding site for chromodomain transcriptional repressor HP1 proteins, which in turn 
recruit other transcriptional repression machinery, such as DNA methyltransferases and histone 
deacetylases (HDACs) to achieve promoter gene silencing (Wang et al., 2000; Nguyen et al., 
2002; Fuks et al., 2003; Lehnertz et al., 2003; Fuks, 2005). Moreover, DNMTs have been also 
shown to directly interact with histone methyltransferase G9a in directing de novo DNA 
methylation and establishing coordinated mechanism of DNA and histone methylation leading 
to gene repression (Esteve et al., 2006; Epztejn-Litman et al., 2008; Dong et al., 2008). Thus, to 
further explore in more molecular detail the role of epigenetic changes in p15, p21, and E-
cadherin gene silencing, we focused on assessing the effect of combinatorial treatments of 
epigenetic inhibitors on gene reactivation.  
Previous studies have indicated that combinations of DNMT and HDAC inhibitors work in 
synergy to induce greater expression of silenced tumor suppressor genes in cancer cell lines 
(Zhu and Otterson, 2003; McGarvey et al., 2006). However, whether there is  or not synergy 
between combinations of DNMT and HMT inhibitors and between HMT inhibitors targeting 
different lysine methylating enzymes on reactivation of epigenetically silenced p15, p21, and E-
cadherin genes in AML, was unknown. 
 Previously, we established that DAC potentiated anti-proliferative response of BIX and 
chaetocin in AML cell lines, but because DAC did not affect AML cell proliferation we could 
only determine whether the presence of DAC affected BIX and chaetocin drug interaction. We 
evaluated the effectiveness of combining BIX and chaetocin by determining CI values. CI 
measures the degree of synergism or antagonism in drug interaction. Combinations of  BIX and 
chaetocin displayed synergistic activity at high effect levels in KG-1a and Kasumi cells, as CI 
values were less than 1 (Table 5.3). The addition of DAC to BIX and chaetocin co-treatment 
caused the CI values to increase to values more than 1 (Table 5.3). This result indicated that 
DAC reduced the effectiveness of BIX and chaetocin interaction, thus affecting synergy. 
Combination of DAC and chaetocin strongly stimulated p15 and E-cadherin expression to 
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greater levels than those caused by individual drug treatments in AML cell lines and also 
decreased promoter DNA and H3K9 methylation. However, changes in promoter demethylation 
were not as significant as that caused by DAC treatment alone suggesting that promoter 
demethylation was principally caused by the presence of the demethylated agent DAC. These 
results were also consistent with our previous findings, suggesting that H3K9 demethylation 
was the dominant epigenetic event necessary for p15 and E-cadherin re-activation. In the case 
of p21, we found p21 re-expression upon treatment with combination of DAC and chaetocin 
and showed that p21 re-expression was associated with increased H3K9 tri-methylation levels.  
Treatment with BIX and chaetocin were also able to induce p15 and E-cadherin re-
expression only in AML-193 cell line and p21 expression in both AML-193 and Kasumi cell 
line. Thus, the mode of action of this treatment varied between cell lines and genes. p15 and E-
cadherin re-expression was accompanied by promoter demethylation but without significant 
changes in H3K9 methylation. Surprisingly, treatment of AML-193 cells with combination of 
BIX and chaetocin caused re-silencing of hypermethylated genes p15 and E-cadherin and more 
importantly we observed that p15 and E-cadherin inactive-promoters were associated with 
increased H3K9 di- and tri-methylation levels. This result suggested that increased promoter 
H3K9 methylation may represent a repressive epigenetic mark that is associated with silenced 
promoter hypermethylation.  
Using combinations of histone methyltransferase inhibitors, BIX and chaetocin, we 
evaluated whether co-ordinated changes in promoter H3K9 di- and tri-methylation are required 
for influencing p15, p21, and E-cadherin re-activation. Interestingly, similar to the result 
observed with a combination of BIX and DAC in AML-193, p15, and E-cadherin genes were 
also re-silenced upon co-treatment with BIX and chaetocin. This silencing was accompanied by 
increased promoter H3K9 tri-methylation, which supported our previous findings and indicated 
that H3K9 tri-methylation may act as repressive epigenetic mark when it is associated with 
silenced hypermethylated promoters. p21 gene in contrast to p15 and E-cadherin was re-
activated with co-treatment of BIX and chaetocin and this re-activation was associated with 
significant increased in promoter H3K9 di- and tri-methylation.  
Further, our results showed that H3K9 demethylation was the dominant epigenetic event in 
re-expressing tumor suppressor genes that were silenced by promoter hypermethylation and that 
loss of DNA methylation indirectly leads to gene reactivation by reducing repressive histone 
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modifications. Hence, these findings corroborate  that high levels of tri-methyl H3K9 mark 
found at promoters of hypermethylated silenced genes function as dominant repressive silent 
mark, as previously proposed (Bird, 2002; Rice et al., 2003; Kondo et al., 2004).  We also 
found that increased H3K9 tri-methylation can be linked to transcriptional activation of tumor 
suppressor genes with unmethylated promoters. Moreover, we determined that treatment of 
AML cell lines with combination of DNMTs and HMT inhibitors have a greater effect on p15, 
p21, and E-cadherin gene re-expression than treatment with individual drugs. This result 
strongly indicates the effectiveness of combinatorial strategies using epigenetic inhibitors in 
treatment of acute myeloid malignancies.  
Taken together, our results allow us to propose strategies for re-expressing genes silenced 
by promoter hypermethylation. The first strategy highlights the importance of combining 
DNMT and HMT inhibitors. Treatment with DAC induces dissociation of DNMT1, SUV39H1, 
and G9a from promoter hypermethylation. This enzyme dissociation and inhibition of 
SUV39H1 and G9a activities by treatment with chaetocin and BIX results in decreased 
promoter H3K9 di- and tri-methylation, which would lead to transcription factors and other 
regulatory machinery such as HAT enzymes to induce activation of gene-promoter and thus 
gene transcription can progress.  The second strategy involves inhibition of SUV39H1 and G9a 
activities.  G9a and SUV-39H1 inhibition results in promoter H3K9 demethylation, which 
allow free lysine residues to undergo other epigenetic modification such as lysine acetylation 
leading to other transcriptional signals to be activated.   
Reactivation of unmethylated tumor suppressor genes in AML does not fit with the 
strategies presented above, since we showed that p21 re-activation was associated with 
increased promoter H3K9 tri-methylation. However, treatment with chaetocin also induced p21 
expression, but in this case p21 re-activation was accompanied by promoter H3K9 
demethylation. Discrepancies between these results only allow us to speculate whether 
inhibition of SUV39H1 activity itself is the important event for p21 re-activation rather than 
changes in H3K9 methylation levels. However, our studies cannot provide further insights on 
this point as we did not evaluate SUV39H1 activity nor its interactions.  
Finally, our findings have strong relevance in using combinatorial treatment of epigenetic 
inhibitors in cancer therapy. Combination of drugs that affect the epigenetic machinery such as 
DNMT and HDAC inhibitors are emerging as cancer therapeutics, particularly in leukemias. In 
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this study, we demonstrated that combining SUV39H1 and G9a inhibitors with DNMT 
inhibitors enhanced DNMT activity in re-expressing hypermethylated and unmethylated 
silenced genes and showed greater effectiveness in epigenetic drug therapies in AML. Since re-
expression of p15, p21, and E-cadherin in AML cell lines requires changes in promoter H3K9 
methylation without undergoing promoter demethylation, it is possible that HMTs inhibitors 
may be more effective than DNMT inhibitors in epigenetic therapies and that may be 
chemotherapeutic toxicity will be reduced. Our study highlights the relevance in determining 
the dominance of epigenetic event in gene re-activation and the need for clinical testing of 
histone methyltransferase inhibitors. Moreover, detailed drug interaction studies are needed in 
order to identify synergy between drug combinations, which would lead to optimal cancer 
epigenetic therapies. 
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7. Future Directions 
In order to continue evaluating the epigenetic mechanism involved in silencing of tumor 
suppressor genes in AML, it will be necessary to determine the association of histone lysine 
methylating enzymes SUV39-H1 and G9a and HDAC enzymes with p15, p21 and E-cadherin 
gene promoters. Further, it will be interesting to determine the interaction between these 
enzymes and other repressor proteins using co-immunoprecipitation assays. The experiments 
performed in this study could also be done evaluating patient material to confirm the results that 
were seen in AML cell lines. 
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